US20210148797A1 - Liquid to liquid biological particle fractionation and concentration - Google Patents
Liquid to liquid biological particle fractionation and concentration Download PDFInfo
- Publication number
- US20210148797A1 US20210148797A1 US17/103,900 US202017103900A US2021148797A1 US 20210148797 A1 US20210148797 A1 US 20210148797A1 US 202017103900 A US202017103900 A US 202017103900A US 2021148797 A1 US2021148797 A1 US 2021148797A1
- Authority
- US
- United States
- Prior art keywords
- sample
- filter
- fluid
- cartridge
- particles
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 title claims abstract description 87
- 238000005194 fractionation Methods 0.000 title claims abstract description 22
- 239000007788 liquid Substances 0.000 title claims description 43
- 238000000034 method Methods 0.000 claims abstract description 84
- 239000012530 fluid Substances 0.000 claims abstract description 76
- 239000012466 permeate Substances 0.000 claims abstract description 17
- 239000011148 porous material Substances 0.000 claims abstract description 11
- 238000004891 communication Methods 0.000 claims abstract description 7
- 230000003247 decreasing effect Effects 0.000 claims abstract description 6
- 239000000523 sample Substances 0.000 claims description 119
- 239000006260 foam Substances 0.000 claims description 41
- 239000012528 membrane Substances 0.000 claims description 38
- 239000012465 retentate Substances 0.000 claims description 23
- 238000010828 elution Methods 0.000 claims description 12
- 239000012468 concentrated sample Substances 0.000 claims description 8
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 239000000919 ceramic Substances 0.000 claims 1
- 239000012149 elution buffer Substances 0.000 claims 1
- 238000011010 flushing procedure Methods 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 description 58
- 238000001514 detection method Methods 0.000 description 43
- 238000004458 analytical method Methods 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- 239000012141 concentrate Substances 0.000 description 25
- 210000004027 cell Anatomy 0.000 description 22
- 238000000605 extraction Methods 0.000 description 20
- 230000008569 process Effects 0.000 description 20
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 16
- 239000000443 aerosol Substances 0.000 description 15
- 230000007613 environmental effect Effects 0.000 description 13
- 102000039446 nucleic acids Human genes 0.000 description 11
- 108020004707 nucleic acids Proteins 0.000 description 11
- 150000007523 nucleic acids Chemical class 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 238000005119 centrifugation Methods 0.000 description 10
- 238000005070 sampling Methods 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
- 238000002955 isolation Methods 0.000 description 8
- 239000000463 material Substances 0.000 description 8
- 238000000926 separation method Methods 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 239000002699 waste material Substances 0.000 description 8
- 241000700605 Viruses Species 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 238000012545 processing Methods 0.000 description 7
- 231100000765 toxin Toxicity 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 6
- 241000282412 Homo Species 0.000 description 6
- 238000001914 filtration Methods 0.000 description 6
- 238000003752 polymerase chain reaction Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 239000003053 toxin Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 241000196324 Embryophyta Species 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920003023 plastic Polymers 0.000 description 5
- 239000004033 plastic Substances 0.000 description 5
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 5
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 5
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 5
- 235000021251 pulses Nutrition 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 241000193738 Bacillus anthracis Species 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 239000001569 carbon dioxide Substances 0.000 description 4
- 229910002092 carbon dioxide Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000005202 decontamination Methods 0.000 description 4
- 230000003588 decontaminative effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000008821 health effect Effects 0.000 description 4
- 238000003018 immunoassay Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000013618 particulate matter Substances 0.000 description 4
- 238000003753 real-time PCR Methods 0.000 description 4
- 210000004215 spore Anatomy 0.000 description 4
- 238000003860 storage Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 3
- 241000607479 Yersinia pestis Species 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 210000004666 bacterial spore Anatomy 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 238000002795 fluorescence method Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000005180 public health Effects 0.000 description 3
- 231100000735 select agent Toxicity 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000013077 target material Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000003612 virological effect Effects 0.000 description 3
- QJZYHAIUNVAGQP-UHFFFAOYSA-N 3-nitrobicyclo[2.2.1]hept-5-ene-2,3-dicarboxylic acid Chemical compound C1C2C=CC1C(C(=O)O)C2(C(O)=O)[N+]([O-])=O QJZYHAIUNVAGQP-UHFFFAOYSA-N 0.000 description 2
- 241000710929 Alphavirus Species 0.000 description 2
- 241001136175 Burkholderia pseudomallei Species 0.000 description 2
- 241000223936 Cryptosporidium parvum Species 0.000 description 2
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 2
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 2
- 241000711950 Filoviridae Species 0.000 description 2
- 241000589602 Francisella tularensis Species 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 102000029797 Prion Human genes 0.000 description 2
- 108091000054 Prion Proteins 0.000 description 2
- 206010037688 Q fever Diseases 0.000 description 2
- 108010039491 Ricin Proteins 0.000 description 2
- 235000004443 Ricinus communis Nutrition 0.000 description 2
- 240000000528 Ricinus communis Species 0.000 description 2
- 241000606697 Rickettsia prowazekii Species 0.000 description 2
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 2
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 2
- 230000001133 acceleration Effects 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 229940065181 bacillus anthracis Drugs 0.000 description 2
- 229920001400 block copolymer Polymers 0.000 description 2
- 235000012206 bottled water Nutrition 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004720 dielectrophoresis Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 229940118764 francisella tularensis Drugs 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 239000012510 hollow fiber Substances 0.000 description 2
- 239000004021 humic acid Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000010030 laminating Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000004417 polycarbonate Substances 0.000 description 2
- 229920000515 polycarbonate Polymers 0.000 description 2
- 238000011045 prefiltration Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 241000223602 Alternaria alternata Species 0.000 description 1
- 241000293034 Apophysomyces elegans Species 0.000 description 1
- 241000712891 Arenavirus Species 0.000 description 1
- 241000228245 Aspergillus niger Species 0.000 description 1
- 241001465318 Aspergillus terreus Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193410 Bacillus atrophaeus Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 241001465178 Bipolaris Species 0.000 description 1
- 241001161772 Bipolaris rostrata Species 0.000 description 1
- 241000266355 Bipolaris tetramera Species 0.000 description 1
- 108030001720 Bontoxilysin Proteins 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 241000589562 Brucella Species 0.000 description 1
- 206010006500 Brucellosis Diseases 0.000 description 1
- 241000722910 Burkholderia mallei Species 0.000 description 1
- 206010069747 Burkholderia mallei infection Diseases 0.000 description 1
- 206010069748 Burkholderia pseudomallei infection Diseases 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000033335 Cladophialophora bantiana Species 0.000 description 1
- 241001508813 Clavispora lusitaniae Species 0.000 description 1
- 241000193163 Clostridioides difficile Species 0.000 description 1
- 241000193155 Clostridium botulinum Species 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000193449 Clostridium tetani Species 0.000 description 1
- 241001445332 Coxiella <snail> Species 0.000 description 1
- 241000606678 Coxiella burnetii Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000223211 Curvularia lunata Species 0.000 description 1
- 208000001490 Dengue Diseases 0.000 description 1
- 206010012310 Dengue fever Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000006825 Eastern Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005804 Eastern equine encephalitis Diseases 0.000 description 1
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 1
- 206010014587 Encephalitis eastern equine Diseases 0.000 description 1
- 206010014612 Encephalitis viral Diseases 0.000 description 1
- 206010014614 Encephalitis western equine Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108050004280 Epsilon toxin Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 101000867232 Escherichia coli Heat-stable enterotoxin II Proteins 0.000 description 1
- 241001646719 Escherichia coli O157:H7 Species 0.000 description 1
- 241000248325 Exophiala dermatitidis Species 0.000 description 1
- 241000710831 Flavivirus Species 0.000 description 1
- 241000427940 Fusarium solani Species 0.000 description 1
- 241000233732 Fusarium verticillioides Species 0.000 description 1
- 201000003641 Glanders Diseases 0.000 description 1
- 244000286779 Hansenula anomala Species 0.000 description 1
- 235000014683 Hansenula anomala Nutrition 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 201000005807 Japanese encephalitis Diseases 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000132887 Lomentospora prolificans Species 0.000 description 1
- 241001539803 Magnusiomyces capitatus Species 0.000 description 1
- 241000555688 Malassezia furfur Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 241000526636 Nipah henipavirus Species 0.000 description 1
- 241000150452 Orthohantavirus Species 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 241001236817 Paecilomyces <Clavicipitaceae> Species 0.000 description 1
- 241000321453 Paranthias colonus Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 241001499975 Phialemoniopsis curvata Species 0.000 description 1
- 241000235645 Pichia kudriavzevii Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000134749 Pleurostoma richardsiae Species 0.000 description 1
- 206010037151 Psittacosis Diseases 0.000 description 1
- 241001465752 Purpureocillium lilacinum Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241001524162 Ramichloridium Species 0.000 description 1
- 241000235525 Rhizomucor pusillus Species 0.000 description 1
- 241000235527 Rhizopus Species 0.000 description 1
- 241000223254 Rhodotorula mucilaginosa Species 0.000 description 1
- 241000606695 Rickettsia rickettsii Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 241000607760 Shigella sonnei Species 0.000 description 1
- 208000001203 Smallpox Diseases 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 241000193996 Streptococcus pyogenes Species 0.000 description 1
- 241001523006 Talaromyces marneffei Species 0.000 description 1
- 241001634961 Trichosporon asahii Species 0.000 description 1
- 241000223231 Trichosporon beigelii Species 0.000 description 1
- 208000034784 Tularaemia Diseases 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 208000028227 Viral hemorrhagic fever Diseases 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 208000005466 Western Equine Encephalomyelitis Diseases 0.000 description 1
- 201000005806 Western equine encephalitis Diseases 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607734 Yersinia <bacteria> Species 0.000 description 1
- 241000607477 Yersinia pseudotuberculosis Species 0.000 description 1
- 241001148128 Yersinia rohdei Species 0.000 description 1
- 239000000061 acid fraction Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 238000009635 antibiotic susceptibility testing Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940092524 bartonella henselae Drugs 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 239000003131 biological toxin Substances 0.000 description 1
- 229940053031 botulinum toxin Drugs 0.000 description 1
- 229940074375 burkholderia mallei Drugs 0.000 description 1
- 230000009172 bursting Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 239000013000 chemical inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 208000025729 dengue disease Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000003292 diminished effect Effects 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 244000053095 fungal pathogen Species 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 238000012165 high-throughput sequencing Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 201000004015 melioidosis Diseases 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 201000000901 ornithosis Diseases 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 239000011860 particles by size Substances 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 238000000275 quality assurance Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940046939 rickettsia prowazekii Drugs 0.000 description 1
- 229940075118 rickettsia rickettsii Drugs 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 238000011896 sensitive detection Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 229940115939 shigella sonnei Drugs 0.000 description 1
- 239000004071 soot Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 206010061393 typhus Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 201000006266 variola major Diseases 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 201000002498 viral encephalitis Diseases 0.000 description 1
- 239000012130 whole-cell lysate Substances 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/405—Concentrating samples by adsorption or absorption
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/20—Accessories; Auxiliary operations
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/22—Controlling or regulating
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/08—Flat membrane modules
- B01D63/082—Flat membrane modules comprising a stack of flat membranes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D63/00—Apparatus in general for separation processes using semi-permeable membranes
- B01D63/08—Flat membrane modules
- B01D63/088—Microfluidic devices comprising semi-permeable flat membranes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2313/00—Details relating to membrane modules or apparatus
- B01D2313/60—Specific sensors or sensor arrangements
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/08—Fully permeating type; Dead-end filtration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2315/00—Details relating to the membrane module operation
- B01D2315/17—Depth filtration, asymmetric membranes arranged with wider pore size side towards feed
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2319/00—Membrane assemblies within one housing
- B01D2319/06—Use of membranes of different materials or properties within one module
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2321/00—Details relating to membrane cleaning, regeneration, sterilization or to the prevention of fouling
- B01D2321/02—Forward flushing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4055—Concentrating samples by solubility techniques
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4005—Concentrating samples by transferring a selected component through a membrane
- G01N2001/4016—Concentrating samples by transferring a selected component through a membrane being a selective membrane, e.g. dialysis or osmosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N2001/4038—Concentrating samples electric methods, e.g. electromigration, electrophoresis, ionisation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N1/00—Sampling; Preparing specimens for investigation
- G01N1/28—Preparing specimens for investigation including physical details of (bio-)chemical methods covered elsewhere, e.g. G01N33/50, C12Q
- G01N1/40—Concentrating samples
- G01N1/4077—Concentrating samples by other techniques involving separation of suspended solids
- G01N2001/4088—Concentrating samples by other techniques involving separation of suspended solids filtration
Definitions
- the subject disclosure relates generally to the field of sample preparation. More particularly, the subject disclosure relates to devices, systems and methods for fractionating and concentrating substances within a fluid sample.
- Dry filters have long been used for collection of aerosols, as well as for collection of particles from liquids.
- dry filters fail primarily for the use of identifying biological particles because detectors generally require a liquid sample and it is extremely difficult to remove the particles into a liquid. Methods for removing particles from flat filters are common but are tedious, inefficient, and require large liquid volumes.
- Centrifugal force is used for the separation of mixtures according to differences in the density of the individual components present in the mixture. This force separates a mixture forming a pellet of relatively dense material at the bottom of the tube. The remaining solution, referred to as the supernate or supernatant liquid, may then be carefully decanted from the tube without disturbing the pellet, or withdrawn using a Pasteur pipette.
- the rate of centrifugation is specified by the acceleration applied to the sample, and is typically measured in revolutions per minute (RPM) or g-forces.
- the particle settling velocity in centrifugation is a function of the particle's size and shape, centrifugal acceleration, the volume fraction of solids present, the density difference between the particle and the liquid, and viscosity of the liquid.
- Centrifugation techniques are tedious in that they are normally made up of multiple steps each requiring a high level of concentration from the operator. Most microbiology laboratories process large numbers of samples by centrifugation on a daily basis. The potential for human error is high due to the tedious nature and automation of these techniques is difficult and costly. Centrifugation also generally requires powered equipment. Thus, many situations, such as emergency response, prevent their use.
- the present subject disclosure presents novel, rapid, efficient one-pass membrane filter based fractionation and concentration devices, systems and methods that fractionate and concentrate particles, and especially biological particles suspended in liquid from a dilute feed suspension (“feed”) into size fractioned and concentrated sample suspensions (retentate), eliminating the separated fluid (permeate) in a separate stream.
- the subject disclosure is particularly useful for the fractionation and concentration of suspended biological particles, such as proteins/toxins, viruses, DNA, and bacteria in the size range of approximately 0.001 micron to 20 microns diameter. Concentration of these particles is advantageous for detection of target particles in a dilute suspension, because concentrating them into a small volume makes them easier to detect.
- Fractionation is performed in “cascade” fashion, in order to concentrate particles below the size cut of each preceding stage remaining in the separated fluid in a concentrated sample suspension.
- This process can also be used to create a “band-pass” concentration for concentration of a particular target size particle within a narrow range.
- the device uses pressure on the feed side, vacuum on the permeate side, and/or mechanical shear to accelerate the separation process, and may include an added surfactant to increase efficiency.
- Integrated pneumatic, hydraulic, or mechanical valving and a novel vacuum startup procedure allow for startup of wet membranes while reducing liquid hold-up volume in the device.
- the cascade filter stack is unique in that the sample flow is perpendicular to the surface of a stack of filters, in series, enclosed in a housing with only a small open interstitial space between each filter with elution of the filters performed by a simultaneous wet foam elution performed parallel, or tangential, to the retentate filter surface through the small interstitial space.
- Foam elution is performed simultaneously one each of the filter stages, so that transmembrane pressure across each membrane during elution remains essentially zero or near to it. In this way, flow of elution fluid through the membranes is eliminated or significantly reduced, so that the tangential flow velocity and elution efficiency are maximized.
- the extraction foam can be prepared from pressurized gas and a surfactant dissolved in the collection fluid.
- the present subject disclosure is a device for fractionation and concentration of particles from a fluid sample.
- the device includes a cartridge containing staged filters having porous surface in series of decreasing pore size for capture of particles from a fluid sample; and a permeate pressure source in fluid communication with the cartridge; wherein the particles are eluted from the porous surfaces and dispensed in a reduced fluid volume.
- the present subject disclosure is a system for fractionation and concentration of particles from a fluid sample.
- the method includes a reservoir holding a fluid sample; a fractionation and concentration cartridge including two or more staged filters; a permeate pressure device in fluid communication with the cartridge; a concentrating unit including an actuating integral valving to move sample through the cartridge; and a fluid dispenser source for collecting concentrated samples from the cartridge staged filters; wherein the fluid sample is moved through the concentrating unit, then the concentrated samples are eluted from the filters and dispensed.
- the present subject disclosure is a system for rapid fractionation and concentration of particles from a fluid sample.
- the system includes introducing a sample into the sample reservoir; initiating a fractionation and concentration cycle; passing the fluid sample through a series of filters; eluting a plurality of particles of decreasing particle size from each filter stage; and extracting a concentrated sample from each filter stage.
- FIG. 1A shows a manifold portion of a five stage fluidics device, according to an exemplary embodiment of the present subject disclosure.
- FIG. 1B shows a clamp portion of a five stage fluidics device, according to an exemplary embodiment of the present subject disclosure.
- FIG. 1C shows an exploded view of a five stage fluidics device, according to an exemplary embodiment of the present subject disclosure.
- FIG. 2 shows an internal fluid volume view of a five stage fluidics device, according to an exemplary embodiment of the present subject disclosure.
- FIG. 3 shows an internal fluid volume view of a two stage fluidics device, according to an exemplary embodiment of the present subject disclosure.
- FIG. 4 shows an internal fluid volume view of a three stage fluidics device, according to an exemplary embodiment of the present subject disclosure.
- FIG. 5 shows a flow chart for fractionation and concentration, according to an exemplary embodiment of the present subject disclosure.
- FIG. 6 shows a two cartridge system, according to an exemplary embodiment of the present subject disclosure.
- FIG. 7A shows a cross sectional view of a two stage filter stack with integral filter supports, according to an exemplary embodiment of the present subject disclosure.
- FIG. 7B shows a cross sectional view of a two stage filter stack with no filter support, according to an exemplary embodiment of the present subject disclosure.
- FIGS. 8A-8X show a flow chart with detailed steps of a process for fractionation and concentration, according to an exemplary embodiment of the present subject disclosure.
- the present subject disclosure relates generally to the fields of bioterrorism security, medicine, and environmental science. Rapid, reliable detection of airborne biothreats is a significant need for the protection of civilians and military personal from pandemic outbreaks and bioterrorist events. Best in class biothreat detection systems use aerosol collectors to capture particles into a liquid volume in the range of 2 to 12 mL. Samples are then processed using a number of sample preparation techniques and analyzed by rapid microbiological methods, including real-time quantitative polymerase chain reaction (qPCR) and ultra-high throughput sequencing (UHTS) and/or gold-standard culture based methods. While the state of the art for rapid detectors, collectors, and identifiers has advanced dramatically in recent years, advancement of sample preparation techniques has lagged significantly and considerable improvements are needed in these techniques.
- qPCR real-time quantitative polymerase chain reaction
- UHTS ultra-high throughput sequencing
- Detect/collect/identify systems for airborne biothreats must operate correctly in all types of indoor and outdoor environments.
- Urban, industrial, and rural outdoor environments as well indoor environments range from very low to very high particle concentrations.
- Detection of threats in these varied environments often hinges on the ability of the system to capture and identify rare threat particles in what can be a highly varied, complex mixture of organic and inorganic debris particles, innocuous microbes, pollen, fungal spores, and mammalian cells.
- Aerosol samples and other samples of importance often contain a significant amount and wide range of non-target debris including organic and inorganic matter and biological materials.
- these non-target materials can significantly affect the performance of sample preparation and agent identification techniques with a common side effect of inhibition.
- Conventional sample preparation techniques exist for removing these inhibitors, but they are slow and perform best when volumes of only a few hundred microliters are processed—demonstrating the mismatch between collected sample size and the volume that can be processed and analyzed by available technologies. This mismatch raises the true system detection limit to levels significantly higher than the desired detection limit and creates a significant likelihood of false negative results when, as would typically be the case, only trace levels of signature are present.
- Detection and identification may key on whole organisms, nucleic acids, or proteins.
- Culture based analysis, antibiotic susceptibility testing, and functional assays all require live organism samples.
- Common nucleic acid techniques include qPCR, UHTS, and hybridization arrays.
- ELISA and other immunoassay techniques, mass spectrometry, chromatography techniques, and other techniques may be used for protein analysis. There are significant reasons in some cases to choose one of these techniques over the other or in some cases to analyze with more than one technique. Additionally some techniques lend themselves to use in autonomous detection platforms and some are used only in laboratory settings.
- the sample preparation system must be capable of autonomous operation for a month or more without maintenance.
- the same environmental particles and inhibitors that commonly cause issues with the identifier can also lead to failure of the sample preparation system, especially after repeated use over extended periods of time.
- the time required for the sample preparation methods used for these complex samples is a large portion of the total time needed for identification and, even so, the methods are only capable of processing a very small portion of the available sample.
- the present subject disclosure presents a novel technique of fractionating multiple components simultaneously. It may be used in numerous fields, including, but not limited to, bioterrorism detection.
- exemplary and specific fields of use include, but are not limited to:
- the present subject disclosure may be used to assist in identifying agents from the following lists:
- Anthrax Bacillus anthracis
- Botulism Clostridium botulinum toxin
- Plague Yersinia pestis
- Smallpox variola major
- Tularemia Francisella tularensis
- Viral hemorrhagic fevers filoviruses [e.g., Ebola, Marburg] and arenaviruses [e.g., Lassa, Machupo])
- Brucellosis Epsilon toxin of Clostridium perfringens Food safety threats (e.g., Salmonella species, Escherichia coli O157:H7, Shigella ) Glanders ( Burkholderia mallei ) Melioidosis ( Burkholderia pseudomallei ) Psittacosis ( Chlamydia psittaci ) Q fever ( Coxiella burnetii ) Ricin toxin from Ricinus communis (castor beans) Staphylococcal enterotoxin B Typhus fever ( Rickettsia prowazekii ) Viral encephalitis (alphaviruses [e.g., Venezuelan equine encephalitis, eastern equine encephalitis, western equine encephalitis]) Water safety threats (e.g., Vibrio cholerae, Cryptosporidium parvum )
- Water safety threats e.g., Vi
- Flaviviruses Yellow fever virus, West Nile virus, Dengue, Japanese Encephalitis
- VEE Alphaviruses
- Mycobacterium tuberculosis drug resistant Mycobacteria other than TB, like C. leprae Streptococcus pneumoniae S. pyogenes S. aureus Clostridium tetani C. difficile Bacillus cereus Coxiella brunette (Q fever) Francisella tularensis Borrelia recurrentis Rickettsia rickettsii R. prowazekii Shigella sonnei Bartonella henselae Yersinia enterolitica Y. pseudotuberculosis Neisseria meningitidis Legionella pneumophila Burkholderia pseudomallei Pasteurella multocida
- the present subject disclosure may be used to assist in identifying various agents of varying sizes:
- Botulinum Toxoid A - 150 to 900 kD or 10 nm to 70 nm (0.01 ⁇ m to 0.07 ⁇ m)(Normally published as 150 kD however some publications state that toxo
- Specific fields of use in the medical field include, but are not limited to:
- the present subject disclosure has been developed as a unique membrane filter based fractionation and concentration system that is capable of separating particles by size and concentrating those particles into small ( ⁇ 100 ⁇ L) sample volumes.
- a novel approach was developed in which the membrane filters are stacked, in order of decreasing pore size, inside a single cartridge with a small interstitial space, or in some cases a solid filter support and further reduced interstitial space, between each membrane filter. Sample flow is introduced perpendicular to the first filter surface and is pushed or pulled, in series, directly through each of the membrane in the cartridge.
- a novel vacuum startup method is used to allow air to be removed from the interstitial space and other internal volume, so that the sample process can be initiated.
- a series of channels and associated valves, integral to the cartridge, are used to link each stage back to a pump to allow for negative pressure to be pulled on the system.
- the sample flow is introduced as described above.
- the entire sample is flowed through the cartridge, until air reaches the first membrane filter and the system locks up.
- the vacuum startup valves are then actuated one by one to allow the remaining fluid to be pushed through the remaining membrane filters.
- the cartridge inlet and outlet valves are closed and a retentate valve is opened on each stage.
- a wet carbonated foam is then introduced into one end of the cartridge, which subsequently travels the length of the cartridge, tangential to the retentate surface of each membrane.
- the foam is dispensed out of the retentate port into a separate sample container for each membrane filter. The foam then breaks down into a liquid leaving a small concentrate fraction associated with each membrane filter stage.
- the subject disclosure of the present application which describes liquid-to-liquid fractionation and concentration devices, systems and methods, provides a novel means of rapidly and efficiently separating and then concentrating biological samples.
- Significant advantages are offered over current methods including, but not limited to: improved separation efficiency, improved concentration efficiency, shorter process times, automation, and integration into automated systems.
- this present technique concentrates the collected sample prior to analysis, but with many further advantages, including but not limited to: 1) the liquid volume of the sample is quickly reduced. Unlike centrifugation, which typically takes 10 to 30 minutes to concentrate micron-sized particles, this process can be accomplished in 5 to 60 seconds for a 10 mL initial volume.
- the sample is passed straight through in one pass. This results in a much smaller volume of liquid on the order of 100 to 400 microliters, or passed straight through in dead-end fashion and then extracted in a volume of liquid or foam in the range of 4 to 400 microliters.
- the sample remains in liquid form for transport and analysis. The detection limit for the target agent is lowered, with respect to the media originally sampled.
- the final sample volume is reduced much further than in previously known methods, while kept in liquid form, allowing detection in devices such as multi-well plate readers that utilize small input samples.
- the reduced-size samples can be more efficiently stored and transported by microfluidic handling methods.
- the device can be constructed to separate particles in one pass into different size fractions for analysis for certain agents. For example, cells and spores can be concentrated separately from viruses and biological toxins. Further, the size range that is concentrated can be narrow, or “band-pass” to concentrate a small size range fraction from a complex matrix, such as an environmental sample 5 )
- the device can be used to reduce the onboard fluid storage capacity of aerosol samplers, by recycling the cleaned liquid back to the collection cycle after the sampled particles are removed into a small volume for analysis.
- This device is much more readily adapted to automated systems than other technologies including centrifugation, flat filtration, and other methods.
- the flow-through nature of the device allows for straightforward configuration into an automated detection system.
- This device is significantly more robust in nature than new microfluidic concentration systems such as dielectrophoresis concentration systems.
- Dielectrophoresis systems developed by Sandia have internal flow paths of small diameters that can create significant clogging during processing of fluids with high particle concentrations.
- Commercially available hollow fiber filters while possessing pores of up to a maximum of approximately 0.5 ⁇ m diameter, will take significantly longer to clog, due to the high number of pores and the tangential flow cleaning with the preferred surfactant foam.
- the InnovaPrep system is much smaller than any commercially available liquid to liquid concentrator. Necessary components can be arranged in such a way as to take advantage of any empty space in the system being integrated. 9) The device it made almost entirely of low cost, readily available components. This significantly lowers the cost of integration and makes it more practical than other methods concentration.
- FIGS. 1A-1C An exemplary embodiment of a device according to the present subject disclosure is presented in FIGS. 1A-1C .
- an exemplary device 100 which can be used for fractionation and concentration of components within a fluid, is presented.
- the device 100 includes a manifold portion 101 , with a manifold mounting flange 111 used to connect or secure the device, and a clamp plate 102 which together serve as end pieces to the device 100 , and the fluidic stack 108 are held within those end pieces.
- Clamping bolts 103 maintain a sealed condition for the device 100 when it is operated.
- Alignment pins 104 serve to maintain the structural integrity of the device and provide an easier method to put all components together.
- Fluid connections 105 are the ports where fluid is introduced into the device 100 .
- Pneumatic control line 106 regulates the pressure within the device 100 .
- FIG. 1C shows an exploded view of a laminated multi-stage concentration cell device 100 with bolts 103 and alignment pins 104 removed for sake of clarity.
- the fluidic stack 108 comprises of numerous layers of hard plastic layers 121 with holes cut out in specific shapes and geometries and fluid paths etched in the surface of, and gaskets 122 enclosing filter portions 123 .
- the device 100 is constructed by compressing alternating layers of plastic 121 and filter media 123 between two fluidic blocks 122 which allow the cell to interface with the rest of the fluidic system.
- This type of cartridge may be constructed using the method shown or may be constructed using bonding and construction techniques that are commonly used in microfluidic device construction.
- An exemplary cartridge is shown having 5 filters. In this case, the 5 membrane filters could be made up with filter types, or similar filter types to that shown below.
- FIG. 7A shows a cross sectional view of a two stage filter stack with integral filter supports.
- This cell is constructed by laminating several layers of different material together to create fluid channels.
- the components are (1) ridged plastic substrate in which fluid paths are etched, (2) soft plastic substrate which functions as a gasket creating a gas and liquid tight seal between layers, (3) filtration media, (4) filter support ridges, and (5) fluid paths connecting one filter stage to the next such that the permeate of the first stage filter becomes the sample of the second stage filter.
- FIG. 7B shows a cross sectional view of a five stage filter stack.
- This cell is also constructed by laminating layers of material together; the filter media is arranged such that the sample travels through all five filter stages in a single step, starting with the largest pore diameter filter and ending with the smallest.
- the components are (6) the sample inlet port, (7) soft or ridged substrate sealing the layers together and creating fluid channels, (8) filtration media, (9) the permeate port. (10) shows the direction of the sample flow.
- FIGS. 1A-1C includes five layers of filters, any number is possible, and the technique to make and use the device will be similar, and understood by one having ordinary skill in the art when considering the present disclosure.
- a fluidic internal volume 200 is created with numerous chambers, passageways and connections. Such internal fluid volume 200 is shown in FIG. 2 . It should be noted that this internal fluidic volume is created as a result of the laser cut passageways of the various hard plastic layers 121 , gaskets 122 , and filters 123 used in the fluidic stack 108 .
- Internal fluidic volume 200 shows various paths for the fluidic stack 108 assembly for a five stage concentrator.
- 202 , 204 and 206 are pneumatic control lines, and used to control filter stage 1 bypass valve (humic acid removal) 202 , Filter stage 2 bypass valve (prefilter) 204 , and decontamination isolation valves 206 .
- Various fluid lines include the decontamination fluid outlet port 208 , the filter stage 3 retentate port (concentration stage 1) 210 , the filter stage 1 retentate port (Humic acid removal) 212 , the filter stage 4 retentate port (concentration stage 2) 214 , the filter stage 2 retentate port (Prefilter) 216 , and the filter stage 5 retentate port (concentration stage 3) 218 .
- Further pneumatic control lines include the filter stage 5 bypass valve (Concentration stage 3) 220 , filter stage 4 bypass valve (concentration stage 2) 222 , filter stage 3 bypass valve (concentration stage 1) 224 , and the master filter isolation valve 226 .
- Further fluid lines include the gas flush port 228 , the foam injection port 230 , the sample inlet port 232 , the sample outlet port (permeate) 234 , and the decontamination fluid inlet port 236 .
- Part of the pneumatic control line is the feed/permeate isolation valve 238 .
- the various filter stages include filter stage 1 250 , filter stage 2 252 , filter stage 3 254 , filter stage 4 256 , and filter stage 5 258 .
- All of the components and internal fluid channels for the five stage fluidic stack shown in FIG. 2 work together in the manner as described in further detail below. It is noted that the five stage fluidic stack shown in FIG. 2 is merely exemplary, and that the present disclosure is not limited to such an exemplary embodiment. For example, a two stage fluidic internal volume is shown in FIG. 3 and a three stage fluidic internal volume is shown in FIG. 4 . Other numbers are also possible and within the purview of one having ordinary skill in the art.
- the components of the two stage fluidics internal volume 300 include:
- the components of the three stage fluidics internal volume 400 include:
- FIG. 5 A process flow diagram for an exemplary system according to the present subject disclosure is presented in FIG. 5 .
- the orange boxes 522 , 525 , 542 , 545 , 547 , 551 contain the final six concentrated fractions that will be recovered from the input sample shown in the red box 501 .
- Two fractionation/concentration fluidics cartridges 510 and 540 will be used to produce the six fractions 522 , 525 , 542 , 545 , 547 , 551 .
- Cartridge A 510 will separate the input sample into fractions containing whole cells 514 , free nucleic acids 522 , and free proteins 525 .
- Cartridge A 510 A portion of the whole cell fraction 514 from Cartridge A 510 will be lysed and then Cartridge B 540 will be used to separate the whole cell lysate 543 into fractions containing cell debris 545 , nucleic acids 547 , and proteins 551 .
- Cartridge A 510 separations will be performed with stages A.1 511 , A.2 513 , A.3 515 , A.4 521 , and A.5 524 .
- Cartridge B 540 will house stages B.1 544 , B.2 548 , and B.3 550 .
- a novel, replenishable media column loaded with Polyvinylpolypyrrolidone (PVPP) media will be used to remove humic substances while allowing target materials to pass.
- Stage A.1 511 will use a large pore membrane to remove environmental debris and inhibitors 530 , including large particulate matter, from the input sample.
- Stage A.2 513 will be a novel, replenishable Polyvinylpolypyrrolidone (PVPP) Sol-gel membrane used to remove humic substances 531 while allowing target materials to pass.
- Stage A.3 515 is used to capture whole viable organisms. A portion of this fraction is then archived for later analysis and a portion is lysed for rapid detection.
- the permeate fluid from this stage will contain free solution nucleic acids and free solution proteins which are subsequently separated into a nucleic acid fraction and a protein fraction with Stages A.4 521 and A.5 524 , respectively.
- the lysed fraction of whole viable cells, to be used for rapid detection, is separated into three fractions containing cellular debris, nucleic acids and proteins with Stages B.1 544 , B.2 548 and B3 550 , respectively.
- the various permeates 512 , 514 , 516 , 523 , 549 are shown to indicate the remaining substances of the process.
- Permeate waste 526 and 552 indicate the end result of the processes of cartridge A 510 and cartridge B 540 , respectively.
- FIG. 6 in conjunction with FIG. 5 , provides a flow schematic of a layout of an exemplary version of a two cartridge system 600 .
- FIGS. 5 and 6 should be considered jointly for the proceeding discussion.
- a sample with a volume of 1 mL to 50 mL is fed into the sample input reservoir.
- a processing cycle is then initiated.
- the first step is preparation of the cartridges 601 , 603 for processing using a novel vacuum startup method. Because the membranes 606 are hydrophilic in nature and are wet for every sample processed after the first, startup requires that air be evacuated from the system 600 so that the liquid samples can be brought into contact with the membranes. It should be noted that only one membrane 606 is pointed out in the figure for sake of clarity, but multiple membranes are shown.
- Stage A.1 511 membrane When the all of the liquid sample passes through the Stage A.1 511 membrane the system will lock up since air will not pass through a wet hydrophilic membrane. A Liquid Flow Switch is then used to determine when the system has locked up and air pressure is applied to the next stage so that liquid can be pushed through the next membrane filter. This process is continued until all the liquid has been evacuated from the system.
- each Stage is extracted simultaneously.
- pressures across each membrane are balanced and flow through the membranes does not occur since the pressure is equal on both sides.
- This process provides for the best possible concentration efficiencies with the smallest resulting extraction volume.
- the extraction process takes place by opening and closing a single extraction fluid valve connected, through internal cartridge fluidics, to each stage.
- the valve is opened for a short period of time (15 to 50 msec) to allow extraction fluid to be dispensed rapidly into the interstitial space between each membrane. Once dispensed the extraction fluid quickly forms wet, viscous foam that travels the length of the membrane and is dispensed into separate capture reservoirs for each stage.
- Concentrates released from Cartridge A 510 will include fractions containing environmental waste debris for disposal, whole cells, free nucleic acids, and free proteins.
- the whole cell concentrate from Cartridge A 510 will be split into an archived sample and a sample available for secondary processing.
- the sample available for secondary processing is then processed using a flow-though mechanical cell lysis system.
- a wet foam elution flush is performed post-lysis to ensure highly efficient and rapid removal of lysed material from the lysis system.
- the subsequent volume of approximately 1 mL of lysed material is then be processed in Cartridge B 540 .
- Cartridge B 540 operation will essentially be identical to that of Cartridge A 510 with the exception that it will only have three membrane stages.
- Stage 1 544 the cellular debris created during the lysis process will be removed.
- Stage 2 548 will capture nucleic acids.
- Stage 3 will capture proteins 550 .
- FIGS. 8A-8X A detailed 24-step process diagram for a single cartridge fractionation/concentration instrument operation is provided in FIGS. 8A-8X .
- the figures clearly demonstrate the action at each step. They will be summarized here.
- the initial state is shown in FIG. 8X as the conclusive step, and indicates that:
- Step 1 is shown in FIG. 8A and indicates that:
- Step 2 is shown in FIG. 8B and indicates that:
- Step 3 is shown in FIG. 8C and indicates that:
- Step 4 is shown in FIG. 8D and indicates that:
- Step 5 is shown in FIG. 8E and indicates that:
- Step 6 is shown in FIG. 8F and indicates that:
- Step 7 is shown in FIG. 8G and indicates that:
- Step 8 is shown in FIG. 8H and indicates that:
- Step 9 is shown in FIG. 8I and indicates that:
- Step 10 is shown in FIG. 8J and indicates that:
- Step 11 is shown in FIG. 8K and indicates that:
- Step 12 is shown in FIG. 8L and indicates that:
- Step 13 is shown in FIG. 8M and indicates that:
- Step 14 is shown in FIG. 8N and indicates that:
- Step 15 is shown in FIG. 8O and indicates that:
- Step 16 is shown in FIG. 8P and indicates that:
- Step 17 is shown in FIG. 8Q and indicates that:
- Step 18 is shown in FIG. 8R and indicates that:
- Step 19 is shown in FIG. 8S and indicates that:
- Step 20 is shown in FIG. 8T and indicates that:
- Step 21 is shown in FIG. 8U and indicates that:
- Step 22 is shown in FIG. 8V and indicates that:
- Step 23 is shown in FIG. 8W and indicates that:
- Step 24 is shown in FIG. 8X and indicates that:
- Sample extraction can be performed into a small volume using foam made from the extraction surfactant. This procedure cleans the concentrator, while simultaneously enhancing extraction efficiency and allowing for greatly reduced retentate volumes.
- a small volume of liquid can be used to create a large volume of foam. Since the boundaries of the bubbles present in the foam must remain intact to remain a foam, the boundaries of the bubbles at the interface of the filter and the extraction foam must always be touching. As the foam sweeps tangentially across the surface of the filters, it sweeps the concentrate through the device. When the foam is extracted from the device and collapses, the remaining product is a small volume of liquid. This volume can be in a range of less than 5 microliters to 1 milliliter.
- the foam may be made in a separate container, and then injected to sweep the sample from the concentrator into the sample collection port.
- a sample loop to measure the amount of liquid used to make the foam is preferred in order to generate samples of consistent size.
- the foam may also be generated with a carbonated surfactant solution. Following carbonation, the solution is agitated by dispensing through an orifice, frit, filter, or capillary tube.
- the surfactant foam extraction methods described here can also be used for extraction and cleaning of other collection surfaces in aerosol samplers and collectors. The use of foam to extract these surfaces can provide a significant increase in extraction efficiency and significant decrease in final sample volume.
- the specification may have presented the method and/or process of the present subject disclosure as a particular sequence of steps. However, to the extent that the method or process does not rely on the particular order of steps set forth herein, the method or process should not be limited to the particular sequence of steps described. As one of ordinary skill in the art would appreciate, other sequences of steps may be possible. Therefore, the particular order of the steps set forth in the specification should not be construed as limitations on the claims. In addition, the claims directed to the method and/or process of the present subject disclosure should not be limited to the performance of their steps in the order written, and one skilled in the art can readily appreciate that the sequences may be varied and still remain within the spirit and scope of the present subject disclosure.
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Water Supply & Treatment (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Dispersion Chemistry (AREA)
- Sampling And Sample Adjustment (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present disclosure provides for devices, systems and methods for fractionation and concentration of particles from a fluid sample. This includes a cartridge containing staged filters having porous surface in series of decreasing pore size for capture of particles from a fluid sample; and a permeate pressure source in fluid communication with the cartridge; wherein the particles are eluted from the porous surfaces and dispensed in a reduced fluid volume.
Description
- This U.S. Patent Application is a continuation of Ser. No. 14/058,193, filed Oct. 18, 2013, now U.S. Pat. No. 10,845,277; which claims priority to U.S. Provisional Patent Application Ser. No. 61/715,451, filed Oct. 18, 2012, the content of which is hereby incorporated by reference herein in its entirety into this disclosure.
- This subject disclosure was made with U.S. Government support under Department of Homeland Security (DHS) Grant No. D12PC00287. The government has certain rights in this subject disclosure.
- The subject disclosure relates generally to the field of sample preparation. More particularly, the subject disclosure relates to devices, systems and methods for fractionating and concentrating substances within a fluid sample.
- The difficulties of detecting and quantifying particles in air and liquids are well known. Existing systems all begin to fail as concentration falls away until eventually, with diminished concentrations of analyte, there is an inability to detect at all. This poses a significant problem for national security where, for example, the postal anthrax attacks of 2001 and the subsequent war on terrorism have revealed shortcomings in the sampling and detection of biothreats. The medical arts are similarly affected by the existing limits on detection, as are the environmental sciences.
- In the fields of biodefense and aerosol research it is common to collect aerosols into a liquid sample using a wet cyclone or similar device. The aerosol is collected into an aqueous sample so that subsequent analysis of biological particles can be performed using standard techniques that primarily require that the sample be contained in liquid. These “wet” collectors have many failings, including: difficulty in maintaining a set fluid volume, difficulties with buildup of particle matter in the device, and requirements for storage of the fluid in varying environmental conditions.
- Dry filters have long been used for collection of aerosols, as well as for collection of particles from liquids. However, dry filters fail primarily for the use of identifying biological particles because detectors generally require a liquid sample and it is extremely difficult to remove the particles into a liquid. Methods for removing particles from flat filters are common but are tedious, inefficient, and require large liquid volumes.
- Concentration of particles from a liquid is traditionally performed using centrifugation. Centrifugal force is used for the separation of mixtures according to differences in the density of the individual components present in the mixture. This force separates a mixture forming a pellet of relatively dense material at the bottom of the tube. The remaining solution, referred to as the supernate or supernatant liquid, may then be carefully decanted from the tube without disturbing the pellet, or withdrawn using a Pasteur pipette. The rate of centrifugation is specified by the acceleration applied to the sample, and is typically measured in revolutions per minute (RPM) or g-forces. The particle settling velocity in centrifugation is a function of the particle's size and shape, centrifugal acceleration, the volume fraction of solids present, the density difference between the particle and the liquid, and viscosity of the liquid.
- Problems with the centrifugation technique limit its applicability. The settling velocity of particles in the micron size range is quite low. Consequently, centrifugal concentration of these particles takes several minutes to several hours. The actual time varies depending on the volume of the sample, the equipment used, and the skill of the operator.
- Centrifugation techniques are tedious in that they are normally made up of multiple steps each requiring a high level of concentration from the operator. Most microbiology laboratories process large numbers of samples by centrifugation on a daily basis. The potential for human error is high due to the tedious nature and automation of these techniques is difficult and costly. Centrifugation also generally requires powered equipment. Thus, many situations, such as emergency response, prevent their use.
- Other concentration techniques have been explored and primarily fall into three technology groups—microfluidic/electrophoretic based, filtration based, and capture based. However, each of these techniques has disadvantages that prevent their use in certain situations.
- In light of the limitations of conventional techniques, what is needed is a single device for fractionating and concentrating a fluid sample into several component concentrations.
- In so doing, the present subject disclosure presents novel, rapid, efficient one-pass membrane filter based fractionation and concentration devices, systems and methods that fractionate and concentrate particles, and especially biological particles suspended in liquid from a dilute feed suspension (“feed”) into size fractioned and concentrated sample suspensions (retentate), eliminating the separated fluid (permeate) in a separate stream. The subject disclosure is particularly useful for the fractionation and concentration of suspended biological particles, such as proteins/toxins, viruses, DNA, and bacteria in the size range of approximately 0.001 micron to 20 microns diameter. Concentration of these particles is advantageous for detection of target particles in a dilute suspension, because concentrating them into a small volume makes them easier to detect. Fractionation is performed in “cascade” fashion, in order to concentrate particles below the size cut of each preceding stage remaining in the separated fluid in a concentrated sample suspension. This process can also be used to create a “band-pass” concentration for concentration of a particular target size particle within a narrow range. The device uses pressure on the feed side, vacuum on the permeate side, and/or mechanical shear to accelerate the separation process, and may include an added surfactant to increase efficiency. Integrated pneumatic, hydraulic, or mechanical valving and a novel vacuum startup procedure allow for startup of wet membranes while reducing liquid hold-up volume in the device. The cascade filter stack is unique in that the sample flow is perpendicular to the surface of a stack of filters, in series, enclosed in a housing with only a small open interstitial space between each filter with elution of the filters performed by a simultaneous wet foam elution performed parallel, or tangential, to the retentate filter surface through the small interstitial space. Foam elution is performed simultaneously one each of the filter stages, so that transmembrane pressure across each membrane during elution remains essentially zero or near to it. In this way, flow of elution fluid through the membranes is eliminated or significantly reduced, so that the tangential flow velocity and elution efficiency are maximized. The extraction foam can be prepared from pressurized gas and a surfactant dissolved in the collection fluid.
- In one exemplary embodiment, the present subject disclosure is a device for fractionation and concentration of particles from a fluid sample. The device includes a cartridge containing staged filters having porous surface in series of decreasing pore size for capture of particles from a fluid sample; and a permeate pressure source in fluid communication with the cartridge; wherein the particles are eluted from the porous surfaces and dispensed in a reduced fluid volume.
- In another exemplary embodiment, the present subject disclosure is a system for fractionation and concentration of particles from a fluid sample. The method includes a reservoir holding a fluid sample; a fractionation and concentration cartridge including two or more staged filters; a permeate pressure device in fluid communication with the cartridge; a concentrating unit including an actuating integral valving to move sample through the cartridge; and a fluid dispenser source for collecting concentrated samples from the cartridge staged filters; wherein the fluid sample is moved through the concentrating unit, then the concentrated samples are eluted from the filters and dispensed.
- In yet another exemplary embodiment, the present subject disclosure is a system for rapid fractionation and concentration of particles from a fluid sample. The system includes introducing a sample into the sample reservoir; initiating a fractionation and concentration cycle; passing the fluid sample through a series of filters; eluting a plurality of particles of decreasing particle size from each filter stage; and extracting a concentrated sample from each filter stage.
-
FIG. 1A shows a manifold portion of a five stage fluidics device, according to an exemplary embodiment of the present subject disclosure. -
FIG. 1B shows a clamp portion of a five stage fluidics device, according to an exemplary embodiment of the present subject disclosure. -
FIG. 1C shows an exploded view of a five stage fluidics device, according to an exemplary embodiment of the present subject disclosure. -
FIG. 2 shows an internal fluid volume view of a five stage fluidics device, according to an exemplary embodiment of the present subject disclosure. -
FIG. 3 shows an internal fluid volume view of a two stage fluidics device, according to an exemplary embodiment of the present subject disclosure. -
FIG. 4 shows an internal fluid volume view of a three stage fluidics device, according to an exemplary embodiment of the present subject disclosure. -
FIG. 5 shows a flow chart for fractionation and concentration, according to an exemplary embodiment of the present subject disclosure. -
FIG. 6 shows a two cartridge system, according to an exemplary embodiment of the present subject disclosure. -
FIG. 7A shows a cross sectional view of a two stage filter stack with integral filter supports, according to an exemplary embodiment of the present subject disclosure. -
FIG. 7B shows a cross sectional view of a two stage filter stack with no filter support, according to an exemplary embodiment of the present subject disclosure. -
FIGS. 8A-8X show a flow chart with detailed steps of a process for fractionation and concentration, according to an exemplary embodiment of the present subject disclosure. - The present subject disclosure relates generally to the fields of bioterrorism security, medicine, and environmental science. Rapid, reliable detection of airborne biothreats is a significant need for the protection of civilians and military personal from pandemic outbreaks and bioterrorist events. Best in class biothreat detection systems use aerosol collectors to capture particles into a liquid volume in the range of 2 to 12 mL. Samples are then processed using a number of sample preparation techniques and analyzed by rapid microbiological methods, including real-time quantitative polymerase chain reaction (qPCR) and ultra-high throughput sequencing (UHTS) and/or gold-standard culture based methods. While the state of the art for rapid detectors, collectors, and identifiers has advanced dramatically in recent years, advancement of sample preparation techniques has lagged significantly and considerable improvements are needed in these techniques.
- Detect/collect/identify systems for airborne biothreats must operate correctly in all types of indoor and outdoor environments. Urban, industrial, and rural outdoor environments as well indoor environments range from very low to very high particle concentrations. Detection of threats in these varied environments often hinges on the ability of the system to capture and identify rare threat particles in what can be a highly varied, complex mixture of organic and inorganic debris particles, innocuous microbes, pollen, fungal spores, and mammalian cells.
- Better automated sample preparation techniques are needed so problems currently associated with detection of rare particles in complex environmental samples can be overcome. Inhibition of identification techniques due to environmental debris is a common problem with these systems due to the varied, high-level complex mixtures of particle and chemical inhibitors. UHTS, qPCR, and other rapid detection techniques can also fail due to high levels of background clutter. Breakdown of bioinformatic systems used for UHTS data analysis due to high background clutter levels is one of the biggest hurdles that must be overcome before cutting-edge sequencing can be adapted to autonomous biothreat detection applications. There is also a significant requirement to be able to differentiate between target agents coming from whole, viable cells and those present as free DNA or free proteins. The inability to rapidly determine if the target particle is a whole viable cell or is only present as free DNA or protein signature, as is the norm in today's biothreat detection systems, does not allow organizations to differentiate between what may be an actual terrorist event from potentially catastrophic false alarms associated with hoaxes or natural events.
- Aerosol samples and other samples of importance (e.g., surface, liquid, clinical, food, etc.), often contain a significant amount and wide range of non-target debris including organic and inorganic matter and biological materials. As described above, these non-target materials can significantly affect the performance of sample preparation and agent identification techniques with a common side effect of inhibition. Conventional sample preparation techniques exist for removing these inhibitors, but they are slow and perform best when volumes of only a few hundred microliters are processed—demonstrating the mismatch between collected sample size and the volume that can be processed and analyzed by available technologies. This mismatch raises the true system detection limit to levels significantly higher than the desired detection limit and creates a significant likelihood of false negative results when, as would typically be the case, only trace levels of signature are present.
- A wide range of existing, and developing, rapid analysis platforms are potentially useful technologies for detection and identification needs. Detection and identification may key on whole organisms, nucleic acids, or proteins. Culture based analysis, antibiotic susceptibility testing, and functional assays all require live organism samples. Common nucleic acid techniques include qPCR, UHTS, and hybridization arrays. ELISA and other immunoassay techniques, mass spectrometry, chromatography techniques, and other techniques may be used for protein analysis. There are significant reasons in some cases to choose one of these techniques over the other or in some cases to analyze with more than one technique. Additionally some techniques lend themselves to use in autonomous detection platforms and some are used only in laboratory settings. Further, it is difficult to determine what techniques may receive precedence in the near future as costs fall or new improved methods are developed. This difficulty in determining what detection and identification system may be used warrants the need for a plug-and-play type of sample preparation system that is capable of delivering the needed sample fractions in a concentrated form for each potential type of analysis.
- Robust, fast, and sensitive detection systems are needed, but currently most systems fail to meet these needs due to deficiencies in sample preparation. The sample preparation system must be capable of autonomous operation for a month or more without maintenance. The same environmental particles and inhibitors that commonly cause issues with the identifier can also lead to failure of the sample preparation system, especially after repeated use over extended periods of time. The time required for the sample preparation methods used for these complex samples is a large portion of the total time needed for identification and, even so, the methods are only capable of processing a very small portion of the available sample.
- The present subject disclosure presents a novel technique of fractionating multiple components simultaneously. It may be used in numerous fields, including, but not limited to, bioterrorism detection. For example, exemplary and specific fields of use include, but are not limited to:
-
- 1. Aerosol sampling for bioterrorism threat agents
- a. Where the sample results in a liquid sample for analysis
- b. Where the sample can contain target agent(s) that are thought to be a substantial threat to the health of humans
- i. Where a list of the potential threat (target) agent(s) can be taken from the U.S. Food and Drug Administration's Centers for Disease Control and Prevention (CDC) Select Agents A, B, or C list (See
List 1, below)
- i. Where a list of the potential threat (target) agent(s) can be taken from the U.S. Food and Drug Administration's Centers for Disease Control and Prevention (CDC) Select Agents A, B, or C list (See
- c. Where the sample can contain target agent(s) that are thought to be a threat to the health of humans, animals or plants, causing societal disruption and economic harm
- i. Where a list of the potential threat (target) agents can be taken from the CDC agent list (http://www.bt.cdc.gov/agent/agentlist.asp), or
List 2, below
- i. Where a list of the potential threat (target) agents can be taken from the CDC agent list (http://www.bt.cdc.gov/agent/agentlist.asp), or
- d. Where the resulting sample can contain test particles, target agent(s) or surrogate(s) in a concentration too small for detection by the chosen method
- i. Where concentration of the sample into a smaller volume can result in detection of the threat agent(s) of interest by one or a combination of the following methods:
- 1. Where detection of the threat agent(s) is performed by polymerase chain reaction (PCR) or PCR-like methods
- 2. Where detection of the threat agent(s) of interest is performed by immunoassay methods
- 3. Where detection of the threat agent(s) of interest is performed by ultraviolet light fluorescence methods
- ii. Or where concentration and analysis resulting in a non-detect result can provide assurance that if the target agent is present, it is present in such a low quantity that the resulting risk to the affected population is minimal
- iii. Where separation of the sample into desirable size fractions can concentrate the target particles into separate but equally concentrated size fractions for analysis by different detection methods listed in 1.c.i. above, such as:
- 1. Separating and concentrating particles larger than 0.2 microns to separate and concentrate bacteria
- iv. Where a small size range or “band-pass” can be separated out and concentrated for interrogation for a particular threat agent or surrogate, such as:
- 1. separating and concentrating particles from 0.2 microns diameter to 2 microns diameter to separate bacterial spores and concentrate them separately from smaller and larger particles present in the initial sample
- 2. separating and concentrating particles from 0.005 microns to 0.2 microns diameter to separate most viruses and concentrate them separately from smaller and larger particles present in the initial sample (examples include viral equine encephalitis, or VEE; 0.06 microns diameter).
- 3. separating and concentrating particles from 0.001 microns (approximately 5 kiloDaltons) to 0.01 microns (approximately 100 kiloDaltons) to separate toxins and proteins and concentrate them separately from smaller and larger particles present in the initial sample
- i. Where concentration of the sample into a smaller volume can result in detection of the threat agent(s) of interest by one or a combination of the following methods:
- 2. The above types of sampling and analysis are performed for the fields of homeland security, corporate security, and military force protection:
- a. Automated sampling and analysis systems such as those developed for government programs Portal Shield, Joint Programs Biological Detection System (JPBDS), US Postal Service Biological Detection System (BDS), and systems under development, such as the Biological Aerosol Networked Detection (BAND) system and Rapid Aerosol Biological Identification System (RABIS)
- b. Manual systems such as bioaerosol collection using air/liquid impingers, including the All Glass Impinger (AGI-30, Ace Glass, Inc., Vineland, N.J.), Greenburg-Smith impingers, and SKC Biosamplers provide samples that are in the 20-100 mL size range, and can be concentrated down to the 4-400 uL volume range using the InnovaPrep device and process described here
- c. Samples resulting from manual swabbing of surfaces onto wetted swabs, pads, or pieces of filter material are often taken for bioterrorism security monitoring and are typically extracted into a volume of liquid resulting in a 2 to 20 mL volume initial sample. Samples like these can be quickly concentrated to much smaller volumes in the range of 4-400 uL using the InnovaPrep
- 3. Water sampling for bioterrorism threat agents
- a. Where the sample can contain target agent(s) that are thought to be a substantial threat to the health of humans by ingestion or contact
- i. Where a list of the potential threat (target) agent(s) can be taken from the U.S. Food and Drug Administration's Centers for Disease Control and Prevention (CDC) Select Agents A, B, or C list (See
List 1, below)
- i. Where a list of the potential threat (target) agent(s) can be taken from the U.S. Food and Drug Administration's Centers for Disease Control and Prevention (CDC) Select Agents A, B, or C list (See
- b. Where the sample can contain target agent(s) that are thought to be a threat to the health of humans, animals or plants, causing societal disruption and economic harm
- i. Where a list of the potential threat (target) agents can be taken from the CDC agent list (http://www.bt.cdc.gov/agent/agentlist.asp), or
List 2, below
- i. Where a list of the potential threat (target) agents can be taken from the CDC agent list (http://www.bt.cdc.gov/agent/agentlist.asp), or
- c. Where the resulting sample can contain test particles, target agent(s) or surrogate(s) in a concentration too small for detection by the chosen method
- i. Where concentration of the sample into a smaller volume can result in detection of the threat agent(s) of interest by one or a combination of the following methods:
- 1. Where detection of the threat agent(s) is performed by polymerase chain reaction (PCR) or PCR-like methods
- 2. Where detection of the threat agent(s) of interest is performed by immunoassay methods
- 3. Where detection of the threat agent(s) of interest is performed by ultraviolet light fluorescence methods
- ii. Or where concentration and analysis resulting in a non-detect result can provide assurance that if the target agent is present, it is present in such a low quantity that the resulting risk to the affected population is minimal
- iii. Where separation of the sample into desirable size fractions can concentrate the target particles into separate but equally concentrated size fractions for analysis by different detection methods listed in 1.c.i. above, such as:
- 1. Separating and concentrating particles larger than 0.2 microns to separate and concentrate bacteria
- iv. Where a small size range or “band-pass” can be separated out and concentrated for interrogation for a particular threat agent or surrogate, such as:
- 1. separating and concentrating particles from 0.2 microns diameter to 2 microns diameter to separate bacterial spores and concentrate them separately from smaller and larger particles present in the initial sample
- 2. separating and concentrating particles from 0.005 microns to 0.2 microns diameter to separate most viruses and concentrate them separately from smaller and larger particles present in the initial sample (examples include viral equine encephalitis, or VEE; 0.06 microns diameter).
- 3. separating and concentrating particles from 0.001 microns (approximately 5 kiloDaltons) to 0.01 microns (approximately 100 kiloDaltons) to separate toxins and proteins and concentrate them separately from smaller and larger particles present in the initial sample
- i. Where concentration of the sample into a smaller volume can result in detection of the threat agent(s) of interest by one or a combination of the following methods:
- a. Where the sample can contain target agent(s) that are thought to be a substantial threat to the health of humans by ingestion or contact
- 4. The above types of sampling and analysis are performed for the fields of homeland security, corporate security, and military force protection:
- a. Water samples taken from water sources used to produce potable water for consumption by the public or government use
- b. Water samples taken to determine a source of production of bioterrorism agents
- c. Water samples taken to determine whether biological decontamination has been effective
- 5. Agricultural samples for bioterrorism threat agents
- a. Where the sample can contain target agent(s) that are thought to be a substantial threat to the health of plants or animals, or indirectly to humans after ingestion of contaminated agricultural products
- b. Where the sample is liquid or can be extracted into a liquid for analysis
- i. Where a list of the potential threat (target) agent(s) can be taken from the U.S. Food and Drug Administration's Centers for Disease Control and Prevention (CDC) Select Agents A, B, or C list (See
List 1, below)
- i. Where a list of the potential threat (target) agent(s) can be taken from the U.S. Food and Drug Administration's Centers for Disease Control and Prevention (CDC) Select Agents A, B, or C list (See
- c. Where the sample can contain target agent(s) that are thought to be a threat to the health of humans, animals or plants, causing societal disruption and economic harm
- i. Where a list of the potential threat (target) agents can be taken from the CDC agent list (http://www.bt.cdc.gov/agent/agentlist.asp), or
List 2, below
- i. Where a list of the potential threat (target) agents can be taken from the CDC agent list (http://www.bt.cdc.gov/agent/agentlist.asp), or
- d. Where the resulting sample can contain test particles, target agent(s) or surrogate(s) in a concentration too small for detection by the chosen method
- i. Where concentration of the sample into a smaller volume can result in detection of the threat agent(s) of interest by one or a combination of the following methods:
- 1. Where detection of the threat agent(s) is performed by polymerase chain reaction (PCR) or PCR-like methods
- 2. Where detection of the threat agent(s) of interest is performed by immunoassay methods
- 3. Where detection of the threat agent(s) of interest is performed by ultraviolet light fluorescence methods
- ii. Or where concentration and analysis resulting in a non-detect result can provide assurance that if the target agent is present, it is present in such a low quantity that the resulting risk to the affected population is minimal
- iii. Where separation of the sample into desirable size fractions can concentrate the target particles into separate but equally concentrated size fractions for analysis by different detection methods listed in 1.c.i. above, such as:
- 1. Separating and concentrating particles larger than 0.2 microns to separate and concentrate bacteria
- iv. Where a small size range or “band-pass” can be separated out and concentrated for interrogation for a particular threat agent or surrogate, such as:
- 1. separating and concentrating particles from 0.2 microns diameter to 2 microns diameter to separate bacterial spores and concentrate them separately from smaller and larger particles present in the initial sample
- 2. separating and concentrating particles from 0.005 microns to 0.2 microns diameter to separate most viruses and concentrate them separately from smaller and larger particles present in the initial sample (examples include viral equine encephalitis, or VEE; 0.06 microns diameter).
- 3. separating and concentrating particles from 0.001 microns (approximately 5 kiloDaltons) to 0.01 microns (approximately 100 kiloDaltons) to separate toxins and proteins and concentrate them separately from smaller and larger particles present in the initial sample
- v. Where exclusion of interferent particles such as diesel soot is desirable to improve the performance of the analysis method [minimization of interference or improvement of “contrast” may be desirable for all fields]
- i. Where concentration of the sample into a smaller volume can result in detection of the threat agent(s) of interest by one or a combination of the following methods:
- 6. The above types of sampling and analysis are performed for the fields of homeland security, corporate security, and military force protection:
- a. Where foodstuffs such as milk is monitored for toxin contamination such as by ricin
- b. Where meatpacking plants are monitored for biological contamination by E. coli, Listeria spp. Such monitoring is also conducted for quality assurance, such as hazard assessment and critical control point (HACCP) programs
- c. For bottled water production
- 1. Aerosol sampling for bioterrorism threat agents
- The present subject disclosure may be used to assist in identifying agents from the following lists:
- List 1: CDC Category A and B Bioterrorism Agents List
- Anthrax (Bacillus anthracis)
Botulism (Clostridium botulinum toxin)
Plague (Yersinia pestis)
Smallpox (variola major)
Tularemia (Francisella tularensis)
Viral hemorrhagic fevers (filoviruses [e.g., Ebola, Marburg] and arenaviruses [e.g., Lassa, Machupo]) - Brucellosis (Brucella species)
Epsilon toxin of Clostridium perfringens
Food safety threats (e.g., Salmonella species, Escherichia coli O157:H7, Shigella)
Glanders (Burkholderia mallei)
Melioidosis (Burkholderia pseudomallei)
Psittacosis (Chlamydia psittaci)
Q fever (Coxiella burnetii)
Ricin toxin from Ricinus communis (castor beans)
Staphylococcal enterotoxin B
Typhus fever (Rickettsia prowazekii)
Viral encephalitis (alphaviruses [e.g., Venezuelan equine encephalitis, eastern equine encephalitis, western equine encephalitis])
Water safety threats (e.g., Vibrio cholerae, Cryptosporidium parvum) - List 2: Secondary Potential Biological Threat Agents
- Flaviviruses (Yellow fever virus, West Nile virus, Dengue, Japanese Encephalitis,
- Nipah virus
Rabies virus
Rhinovirus (could be modified?) - Mycobacterium tuberculosis, drug resistant
Mycobacteria other than TB, like C. leprae
Streptococcus pneumoniae
S. pyogenes
S. aureus
Clostridium tetani
C. difficile
Bacillus cereus
Coxiella brunette (Q fever)
Francisella tularensis
Borrelia recurrentis
Rickettsia rickettsii
R. prowazekii
Shigella sonnei
Bartonella henselae
Yersinia enterolitica
Y. pseudotuberculosis
Neisseria meningitidis
Legionella pneumophila
Burkholderia pseudomallei
Pasteurella multocida - Cryptosporidium parvum
Histoplasma capsulatum
Cryptococcus neoformans
Aspergillus niger - Alternaria alternate
Apophysomyces elegans
Aspergillus terreus - Bipolaris spicifera
Blastoschizomyces capitatus
Candida krusei
Candida lusitaniae
Cladophialophora bantiana
Cunnihamella berholletiae
Curvularia lunata
Exserohilum rostratum
Fusarium moniliforme
Fusarium solani
Hansenula anomala
Lasiodilodia theobromae
Malassezia furfur
Paecilomyces lilacinus
Paecilomyces bariotii
Penicillium marneffei
Phialemonium curvatum
Philophora parasitica
P. richardsiae - Rhizomucor pusillus
Rhizopus rhizopodiformus
Rhodotorula rubra
Saccharomyces cerevisiae
Scedosporium prolificans
Trichosporon beigelii (T. asahii)
Wangiella dermatitidis - The present subject disclosure may be used to assist in identifying various agents of varying sizes:
- The U.S. public health system and primary healthcare providers must be prepared to address various biological agents, including pathogens that are rarely seen in the United States. High-priority agents include organisms that pose a risk to national security because they
-
- can be easily disseminated or transmitted from person to person;
- result in high mortality rates and have the potential for major public health impact;
- might cause public panic and social disruption; and
- require special action for public health preparedness.
- Second highest priority agents include those that
-
- are moderately easy to disseminate;
- result in moderate morbidity rates and low mortality rates; and
- require specific enhancements of CDC's diagnostic capacity and enhanced disease surveillance.
- Third highest priority agents include emerging pathogens that could be engineered for mass dissemination in the future because of
-
- availability;
- ease of production and dissemination; and
- potential for high morbidity and mortality rates and major health impact
- Target:
-
Bacillus thuringiensis endospore - approximately 1 μm Bacillus anthracis endospore - approximately 1 μm Yersinia pestis - Gram negative rod-ovoid 0.5-0.8 μm in width and 1- 3 μm in length Yersinia rohdei - approximately 1 μm Venezuelan Equine Encephalitis - 70 nm (0.07 μm) Gamma-killed MS2 - 2 mD or about 25 nm (0.025 μm) (but will pass through a 300 kD pore size but is retained by a 100 kD pore size Wick and McCubbin - ECBC) Ovalbumin - 45 kD or 6 nm (0.006 μm) Botulinum Toxoid A - 150 to 900 kD or 10 nm to 70 nm (0.01 μm to 0.07 μm)(Normally published as 150 kD however some publications state that toxoid A can be released as complexes comprised of the 150 kD toxin protein along with associated non-toxin proteins and can therefore be released in 900 kD, 500 kD, and 300 kD forms. DNA - 1000 Bp or 600 kD up to 15,000 Bp or 9 mD - Specific fields of use in the medical field include, but are not limited to:
-
- 1. The above types of sampling and analysis are performed for the fields of medical research and diagnostics:
- a. In cancer research where very low concentrations of experimental drugs in body fluids or urine are the targets of analysis
- b. In allergy diagnosis where low quantities of specific antigens are the targets of analysis in body fluids
- c. In health effects research regarding the determination of health effects known to be caused by various materials in inhaled particulate matter with aerodynamic diameter below 2.5 microns (PM 2.5). this area overlaps with environmental studies (see below).
- d. In forensic medicine where low concentrations of toxins or venoms are the targets of analysis in body fluids
- e. In operating rooms [surface extraction and air monitoring, add]
- f. In pharmaceutical manufacturing where the biological aerosol particulate matter concentration is regulated by the US Food and Drug Administration
- 1. The above types of sampling and analysis are performed for the fields of medical research and diagnostics:
- Specific fields of use in the environmental studies field include, but are not limited to:
- [similar to outline above, modified to fit the environmental applications]
-
- 2. The above types of sampling and analysis are performed for the field of environmental study:
- a. In health effects research regarding the determination of health effects known to be caused by various materials in inhaled particulate matter with aerodynamic diameter below 2.5 microns (PM 2.5)
- b. High altitude aerosol research where low quantities of particulate are collected and must be concentrated for study
- c. In cleanrooms where very low aerosol concentrations of aerosol particles are collected for monitoring aimed at source control
- d. For separation of populations of particles collected at different heights above the ground (profiling studies)
- 2. The above types of sampling and analysis are performed for the field of environmental study:
- The present subject disclosure has been developed as a unique membrane filter based fractionation and concentration system that is capable of separating particles by size and concentrating those particles into small (<100 μL) sample volumes. A novel approach was developed in which the membrane filters are stacked, in order of decreasing pore size, inside a single cartridge with a small interstitial space, or in some cases a solid filter support and further reduced interstitial space, between each membrane filter. Sample flow is introduced perpendicular to the first filter surface and is pushed or pulled, in series, directly through each of the membrane in the cartridge. Because the cartridge can be designed for reuse, and because wet hydrophilic membrane filters will not allow air to flow through at pressures below the bubble point, a novel vacuum startup method is used to allow air to be removed from the interstitial space and other internal volume, so that the sample process can be initiated. A series of channels and associated valves, integral to the cartridge, are used to link each stage back to a pump to allow for negative pressure to be pulled on the system.
- After negative pressure has been pulled on the system, the sample flow is introduced as described above. The entire sample is flowed through the cartridge, until air reaches the first membrane filter and the system locks up. The vacuum startup valves are then actuated one by one to allow the remaining fluid to be pushed through the remaining membrane filters. When then entire sample volume has been processed then the cartridge inlet and outlet valves are closed and a retentate valve is opened on each stage. A wet carbonated foam is then introduced into one end of the cartridge, which subsequently travels the length of the cartridge, tangential to the retentate surface of each membrane. Finally the foam is dispensed out of the retentate port into a separate sample container for each membrane filter. The foam then breaks down into a liquid leaving a small concentrate fraction associated with each membrane filter stage.
- The subject disclosure of the present application, which describes liquid-to-liquid fractionation and concentration devices, systems and methods, provides a novel means of rapidly and efficiently separating and then concentrating biological samples. Significant advantages are offered over current methods including, but not limited to: improved separation efficiency, improved concentration efficiency, shorter process times, automation, and integration into automated systems. Like centrifugation, filtration, and the other conventional methods, this present technique concentrates the collected sample prior to analysis, but with many further advantages, including but not limited to: 1) the liquid volume of the sample is quickly reduced. Unlike centrifugation, which typically takes 10 to 30 minutes to concentrate micron-sized particles, this process can be accomplished in 5 to 60 seconds for a 10 mL initial volume. Unlike conventional hollow fiber filter concentration, in which the initial sample is recycled many times through the filter taking from several minutes to hours in order to concentrate a particle such as a protein or enzyme into a volume of several milliliters, the sample is passed straight through in one pass. This results in a much smaller volume of liquid on the order of 100 to 400 microliters, or passed straight through in dead-end fashion and then extracted in a volume of liquid or foam in the range of 4 to 400 microliters. Unlike typical single-pass flat filtration, the sample remains in liquid form for transport and analysis. The detection limit for the target agent is lowered, with respect to the media originally sampled. 2) The final sample volume is reduced much further than in previously known methods, while kept in liquid form, allowing detection in devices such as multi-well plate readers that utilize small input samples. 3) The reduced-size samples can be more efficiently stored and transported by microfluidic handling methods. 4) The device can be constructed to separate particles in one pass into different size fractions for analysis for certain agents. For example, cells and spores can be concentrated separately from viruses and biological toxins. Further, the size range that is concentrated can be narrow, or “band-pass” to concentrate a small size range fraction from a complex matrix, such as an environmental sample 5) The device can be used to reduce the onboard fluid storage capacity of aerosol samplers, by recycling the cleaned liquid back to the collection cycle after the sampled particles are removed into a small volume for analysis. 6) This device is much more readily adapted to automated systems than other technologies including centrifugation, flat filtration, and other methods. The flow-through nature of the device allows for straightforward configuration into an automated detection system. 7) This device is significantly more robust in nature than new microfluidic concentration systems such as dielectrophoresis concentration systems. Dielectrophoresis systems developed by Sandia have internal flow paths of small diameters that can create significant clogging during processing of fluids with high particle concentrations. Commercially available hollow fiber filters, while possessing pores of up to a maximum of approximately 0.5 μm diameter, will take significantly longer to clog, due to the high number of pores and the tangential flow cleaning with the preferred surfactant foam. 8) The InnovaPrep system is much smaller than any commercially available liquid to liquid concentrator. Necessary components can be arranged in such a way as to take advantage of any empty space in the system being integrated. 9) The device it made almost entirely of low cost, readily available components. This significantly lowers the cost of integration and makes it more practical than other methods concentration.
- An exemplary embodiment of a device according to the present subject disclosure is presented in
FIGS. 1A-1C . In these figures, anexemplary device 100, which can be used for fractionation and concentration of components within a fluid, is presented. Thedevice 100 includes amanifold portion 101, with amanifold mounting flange 111 used to connect or secure the device, and aclamp plate 102 which together serve as end pieces to thedevice 100, and thefluidic stack 108 are held within those end pieces. Clampingbolts 103 maintain a sealed condition for thedevice 100 when it is operated. Alignment pins 104 serve to maintain the structural integrity of the device and provide an easier method to put all components together.Fluid connections 105 are the ports where fluid is introduced into thedevice 100.Pneumatic control line 106 regulates the pressure within thedevice 100. -
FIG. 1C shows an exploded view of a laminated multi-stageconcentration cell device 100 withbolts 103 andalignment pins 104 removed for sake of clarity. Thefluidic stack 108 comprises of numerous layers of hard plastic layers 121 with holes cut out in specific shapes and geometries and fluid paths etched in the surface of, andgaskets 122 enclosingfilter portions 123. Thedevice 100 is constructed by compressing alternating layers ofplastic 121 and filtermedia 123 between twofluidic blocks 122 which allow the cell to interface with the rest of the fluidic system. This type of cartridge may be constructed using the method shown or may be constructed using bonding and construction techniques that are commonly used in microfluidic device construction. An exemplary cartridge is shown having 5 filters. In this case, the 5 membrane filters could be made up with filter types, or similar filter types to that shown below. -
- Filter 1-6 μm track-etched polycarbonate membrane filter for large particle removal
-
Filter 2—Affinity based filter for removal of humics -
Filter 3—0.4 μm track-etched polycarbonate membrane filter for bacteria capture -
Filter 4—0.02 μm block copolymer membrane filter for virus and nucleic acid capture -
Filter 5—10 kD block copolymer membrane filter for protein capture
In this way the system would produce fractions of target particles containing the following particle types, with reduced numbers or concentrations of interfering particles or humics. - Whole Bacteria
- Viruses and free nucleic acids
- Proteins
-
FIG. 7A shows a cross sectional view of a two stage filter stack with integral filter supports. This cell is constructed by laminating several layers of different material together to create fluid channels. The components are (1) ridged plastic substrate in which fluid paths are etched, (2) soft plastic substrate which functions as a gasket creating a gas and liquid tight seal between layers, (3) filtration media, (4) filter support ridges, and (5) fluid paths connecting one filter stage to the next such that the permeate of the first stage filter becomes the sample of the second stage filter. -
FIG. 7B shows a cross sectional view of a five stage filter stack. This cell is also constructed by laminating layers of material together; the filter media is arranged such that the sample travels through all five filter stages in a single step, starting with the largest pore diameter filter and ending with the smallest. The components are (6) the sample inlet port, (7) soft or ridged substrate sealing the layers together and creating fluid channels, (8) filtration media, (9) the permeate port. (10) shows the direction of the sample flow. - It should be noted that although the exemplary embodiment shown in
FIGS. 1A-1C includes five layers of filters, any number is possible, and the technique to make and use the device will be similar, and understood by one having ordinary skill in the art when considering the present disclosure. - Once the
device 100 is properly aligned withalignment pins 104 and securely fastened withbolts 103, a fluidicinternal volume 200 is created with numerous chambers, passageways and connections. Suchinternal fluid volume 200 is shown inFIG. 2 . It should be noted that this internal fluidic volume is created as a result of the laser cut passageways of the various hard plastic layers 121,gaskets 122, and filters 123 used in thefluidic stack 108. - Internal
fluidic volume 200 shows various paths for thefluidic stack 108 assembly for a five stage concentrator. 202, 204 and 206 are pneumatic control lines, and used to controlfilter stage 1 bypass valve (humic acid removal) 202,Filter stage 2 bypass valve (prefilter) 204, anddecontamination isolation valves 206. - Various fluid lines include the decontamination
fluid outlet port 208, thefilter stage 3 retentate port (concentration stage 1) 210, thefilter stage 1 retentate port (Humic acid removal) 212, thefilter stage 4 retentate port (concentration stage 2) 214, thefilter stage 2 retentate port (Prefilter) 216, and thefilter stage 5 retentate port (concentration stage 3) 218. - Further pneumatic control lines include the
filter stage 5 bypass valve (Concentration stage 3) 220,filter stage 4 bypass valve (concentration stage 2) 222,filter stage 3 bypass valve (concentration stage 1) 224, and the masterfilter isolation valve 226. - Further fluid lines include the
gas flush port 228, thefoam injection port 230, thesample inlet port 232, the sample outlet port (permeate) 234, and the decontaminationfluid inlet port 236. Part of the pneumatic control line is the feed/permeate isolation valve 238. Finally, the various filter stages includefilter stage 1 250,filter stage 2 252,filter stage 3 254,filter stage 4 256, andfilter stage 5 258. - All of the components and internal fluid channels for the five stage fluidic stack shown in
FIG. 2 work together in the manner as described in further detail below. It is noted that the five stage fluidic stack shown inFIG. 2 is merely exemplary, and that the present disclosure is not limited to such an exemplary embodiment. For example, a two stage fluidic internal volume is shown inFIG. 3 and a three stage fluidic internal volume is shown inFIG. 4 . Other numbers are also possible and within the purview of one having ordinary skill in the art. - For sake of completeness, the components of the two stage fluidics
internal volume 300 include: -
- 301 Microvalve control pneumatic control diaphragm (7 shown)
- 302 Micro fluidic valve (7 shown)
- 303 (pneumatic control line)
Filter stage 1 bypass valve - 304 (Fluid line) Sample outlet (Permeate)
- 305 (Fluid line) Sample inlet (Feed)
- 306 (Fluid line)
Filter stage 1 retentate - 307 (Fluid line)
Filter stage 2 retentate - 308 (pneumatic control line) Master filter isolation valve
- 309 (pneumatic control line)
Filter stage 2 bypass valve - 310 (Fluid line) Foam injection port
- 311
Filter stage 1 - 312
Filter stage 2
- For sake of completeness, the components of the three stage fluidics
internal volume 400 include: -
- 401
Stage 1 foam inlet - 402
Stage 1 foam microvalve - 403
Stage 2 foam inlet - 404
Stage 2 foam microvalve - 405
Stage 3 foam inlet - 406
Stage 3 foam microvalve - 407
Filter stage 1 bypass valve - 408
Filter stage 2 bypass valve - 409 Sample inlet (feed)
- 410
Stage 1 retentate outlet -
411 Stage 1 retentate valve - 412
Stage 2 retentate outlet - 413
Stage 2 retentate valve - 414
Stage 3 retentate outlet - 415
Stage 3 retentate valve - 416
Filter stage 1 - 417
Filter stage 2 - 418
Filter stage 3
- 401
- A process flow diagram for an exemplary system according to the present subject disclosure is presented in
FIG. 5 . Theorange boxes red box 501. Two fractionation/concentration fluidics cartridges fractions Cartridge A 510 will separate the input sample into fractions containingwhole cells 514, freenucleic acids 522, andfree proteins 525. A portion of thewhole cell fraction 514 fromCartridge A 510 will be lysed and thenCartridge B 540 will be used to separate thewhole cell lysate 543 into fractions containingcell debris 545,nucleic acids 547, andproteins 551. Cartridge A 510 separations will be performed with stages A.1 511, A.2 513, A.3 515, A.4 521, and A.5 524.Cartridge B 540 will house stages B.1 544, B.2 548, and B.3 550. Prior toCartridge A 510, a novel, replenishable media column loaded with Polyvinylpolypyrrolidone (PVPP) media will be used to remove humic substances while allowing target materials to pass. Stage A.1 511 will use a large pore membrane to remove environmental debris andinhibitors 530, including large particulate matter, from the input sample. Stage A.2 513 will be a novel, replenishable Polyvinylpolypyrrolidone (PVPP) Sol-gel membrane used to removehumic substances 531 while allowing target materials to pass. Stage A.3 515 is used to capture whole viable organisms. A portion of this fraction is then archived for later analysis and a portion is lysed for rapid detection. The permeate fluid from this stage will contain free solution nucleic acids and free solution proteins which are subsequently separated into a nucleic acid fraction and a protein fraction with Stages A.4 521 and A.5 524, respectively. The lysed fraction of whole viable cells, to be used for rapid detection, is separated into three fractions containing cellular debris, nucleic acids and proteins with Stages B.1 544, B.2 548 andB3 550, respectively. The various permeates 512, 514, 516, 523, 549 are shown to indicate the remaining substances of the process.Permeate waste cartridge A 510 andcartridge B 540, respectively. -
FIG. 6 , in conjunction withFIG. 5 , provides a flow schematic of a layout of an exemplary version of a twocartridge system 600.FIGS. 5 and 6 should be considered jointly for the proceeding discussion. During operation, a sample with a volume of 1 mL to 50 mL is fed into the sample input reservoir. A processing cycle is then initiated. The first step is preparation of thecartridges membranes 606 are hydrophilic in nature and are wet for every sample processed after the first, startup requires that air be evacuated from thesystem 600 so that the liquid samples can be brought into contact with the membranes. It should be noted that only onemembrane 606 is pointed out in the figure for sake of clarity, but multiple membranes are shown. Pulling negative pressure on each stage within thecartridges cartridges way valve - When the vacuum startup is complete the sample is processed through a PVPP column for humic removal followed by
Cartridge A Cartridge A membranes 606 is small (less than 300 μL) and because the membranes are arranged in series the total hold-up volume inCartridge A Cartridge A - When the entire sample has been processed each Stage is extracted simultaneously. By performing the extraction process simultaneously, pressures across each membrane are balanced and flow through the membranes does not occur since the pressure is equal on both sides. This process provides for the best possible concentration efficiencies with the smallest resulting extraction volume. The extraction process takes place by opening and closing a single extraction fluid valve connected, through internal cartridge fluidics, to each stage. The valve is opened for a short period of time (15 to 50 msec) to allow extraction fluid to be dispensed rapidly into the interstitial space between each membrane. Once dispensed the extraction fluid quickly forms wet, viscous foam that travels the length of the membrane and is dispensed into separate capture reservoirs for each stage.
- Concentrates released from
Cartridge A 510 will include fractions containing environmental waste debris for disposal, whole cells, free nucleic acids, and free proteins. The whole cell concentrate fromCartridge A 510 will be split into an archived sample and a sample available for secondary processing. The sample available for secondary processing is then processed using a flow-though mechanical cell lysis system. A wet foam elution flush is performed post-lysis to ensure highly efficient and rapid removal of lysed material from the lysis system. The subsequent volume of approximately 1 mL of lysed material is then be processed inCartridge B 540. -
Cartridge B 540 operation will essentially be identical to that ofCartridge A 510 with the exception that it will only have three membrane stages. InStage 1 544 the cellular debris created during the lysis process will be removed.Stage 2 548 will capture nucleic acids.Stage 3 will captureproteins 550. - A detailed 24-step process diagram for a single cartridge fractionation/concentration instrument operation is provided in
FIGS. 8A-8X . The figures clearly demonstrate the action at each step. They will be summarized here. - The initial state is shown in
FIG. 8X as the conclusive step, and indicates that: -
- All valves are closed
- Syringe is homed
- Rotary valve is at position 1 (waste)
- The cell is filled with NaOH storage solution
- The sample has been placed in the feed reservoir
-
Step 1 is shown inFIG. 8A and indicates that: -
- The user is prompted to: “Place a waste container under the retentate ports” and press “OK”
- The rotary valve rotates CW to position 6 (NaOH reservoir)
-
Step 2 is shown inFIG. 8B and indicates that: -
- The syringe draws 3 mL of NaOH
-
Step 3 is shown inFIG. 8C and indicates that: -
- The Rotary valve rotates CCW to position 2 (NaOH inlet)
- The Humic Stage Iso. valves open
- The syringe slowly pushes all 3 mL of NaOH through the cell (˜6 mL/min)
-
Step 4 is shown inFIG. 8D and indicates that: -
- The syringe completes its stroke
- The following valves change state simultaneously:
- Bypass Valves 1-5 open
- The isolation valves open
- The Humic Stage Iso. valves close
-
Step 5 is shown inFIG. 8E and indicates that: -
- The Gas Valve pulses to force the NaOH out the retentate ports
-
Step 6 is shown inFIG. 8F and indicates that: -
- The foam valve pulses several times to rinse the cell
-
Step 7 is shown inFIG. 8G and indicates that: -
- The Gas Valve pulses to push out the rest of the foam
-
Step 8 is shown inFIG. 8H and indicates that: -
- The user is prompted to: “Place a sample container under the retentate ports” and press “Ok”
- The following valves change position simultaneously:
- The Isolation Valves close
- The Feed/Perm Iso. Valves open
- The Humic Stage Iso. Valves open
- The syringe draws its full volume
-
Step 9 is shown inFIG. 8I and indicates that: -
- Diagnostic: The cell should now be at a full vacuum, from now until
Step 12, the pressure should not increase by a significant amount. The user should be prompted if it is beyond the limit. - The following valves change position simultaneously:
- Filter Bypasses 1-5 close
- Humic Stage Iso. Valves close
- Rotary valve rotates CCW to position 1 (waste)
- The syringe expels its full volume
- Diagnostic: The cell should now be at a full vacuum, from now until
-
Step 10 is shown inFIG. 8J and indicates that: -
- Rotary valve rotates CW to position 5 (Feed Reservoir)
- The syringe draws in the feed sample
-
Step 11 is shown inFIG. 8K and indicates that: -
- The Feed Fluid Sensor sees no fluid
- The syringe draws and additional 10 mL of air
-
Step 12 is shown inFIG. 8L and indicates that: -
- The rotary valve rotates CCW to position 4 (blocked)
- The syringe draws full volume
-
Step 13 is shown inFIG. 8M and indicates that: -
- The rotary valve rotates CCW to position 3 (Cell inlet)
- The syringe starts driving the feed sample at the pressure setpoint
-
Step 14 is shown inFIG. 8N and indicates that: -
- The Inlet Fluid Sensor sees no fluid
- The first stage locks up and the syringe must stop to prevent exceeding the pressure setpoint
-
Step 15 is shown inFIG. 8O and indicates that: -
- As each stage locks up, the Bypass valve for that stage is opened allowing air to pass around the filter
-
Step 16 is shown inFIG. 8P and indicates that: -
- After the final Filter Bypass valve has been opened, the pressure will drop rapidly to ambient
- The syringe continues its stroke to expel its full volume
-
Step 17 is shown inFIG. 8Q and indicates that: -
- The syringe completes its stroke
- All of the Bypass valves close
- The Feed/Perm Iso. valves close
- The Isolation valves open
-
Step 18 is shown inFIG. 8R and indicates that: -
- The Foam Valve pulses to elute the cell
-
Step 19 is shown inFIG. 8S and indicates that: -
- The Gas Valve pulses to push out the remaining foam
- The user is prompted: “Elute again” or “Complete run”
- If “Elute again”; repeat steps 18 and 19
- If “Complete run”; continue to step 20
-
Step 1 is shown inFIG. 8A and indicates that:
-
Step 20 is shown inFIG. 8T and indicates that: -
- The following valves change position simultaneously:
- The Isolation Valves close
- The Filter Bypass Valves 1-5 open
- The Feed/Perm Iso. Valves open
- The Humic Stage Iso. Valves open
- After a short pause, the syringe draws its full volume
- The following valves change position simultaneously:
-
Step 21 is shown inFIG. 8U and indicates that: -
- The rotary valve rotates CCW to position 1 (waste)
- The Feed/Perm Iso. Valves close
- The Filter Bypass Valves 1-5 close
- The syringe expels it's full volume
-
Step 22 is shown inFIG. 8V and indicates that: -
- The rotary valve rotates CW to position 6 (NaOH reservoir)
- The syringe draws 4 mL
-
Step 23 is shown inFIG. 8W and indicates that: -
- The rotary valve rotates CCW to position 2 (NaOH inlet)
- The syringe slowly pushes the NaOH into the cell (˜6 mL/min)
- 3 mL of the fluid fills the inside of the cell, while the additional 1 mL back flushes the humic stage and goes to waste
-
Step 24 is shown inFIG. 8X and indicates that: -
- The Humic Stage Iso. Valves close
- The rotary valve rotates CCW to position 1 (waste)
- The system resets
- The foam extraction process is summarized below. Sample extraction can be performed into a small volume using foam made from the extraction surfactant. This procedure cleans the concentrator, while simultaneously enhancing extraction efficiency and allowing for greatly reduced retentate volumes. A small volume of liquid can be used to create a large volume of foam. Since the boundaries of the bubbles present in the foam must remain intact to remain a foam, the boundaries of the bubbles at the interface of the filter and the extraction foam must always be touching. As the foam sweeps tangentially across the surface of the filters, it sweeps the concentrate through the device. When the foam is extracted from the device and collapses, the remaining product is a small volume of liquid. This volume can be in a range of less than 5 microliters to 1 milliliter. In its simplest form, the foam may be made in a separate container, and then injected to sweep the sample from the concentrator into the sample collection port. However, the use of a sample loop to measure the amount of liquid used to make the foam is preferred in order to generate samples of consistent size. In addition to surfactant foams that are generated by mixing air and a surfactant solution the foam may also be generated with a carbonated surfactant solution. Following carbonation, the solution is agitated by dispensing through an orifice, frit, filter, or capillary tube. The surfactant foam extraction methods described here can also be used for extraction and cleaning of other collection surfaces in aerosol samplers and collectors. The use of foam to extract these surfaces can provide a significant increase in extraction efficiency and significant decrease in final sample volume. Foam made using pressurized carbon dioxide has been shown in our experiments to be compatible with collection of viable Bacillus atrophaeus spores. A US Army Natick Research and Development Engineering Center report, Natick/TR-94/019, also indicates that Bacillus stereothermophilus spore suspensions in buffered carbonated solutions were not harmed, but that germination was inhibited. This inhibition was reversed upon plating for enumeration. It is also known that carbon dioxide inhibits the growth of many microorganisms. This fact has been exploited in preventing bacterial food spoilage in food by using modified atmosphere packing (MAP, e.g., Baker, R. C., et. al., 1986, Effect of an elevated level of carbon dioxide containing atmosphere on the growth of spoilage and pathogenic bacteria at 2, 5, and 13 C. Poult. Sci. 65: 729-737). The inventors believe, based on data contained in the referenced report, that storage of the extraction buffer under carbon dioxide pressure will preserve the extraction fluid from growth of contaminants. Further, since the foam generation method is driven by the evolution of gas from the dissolved state in the surfactant extraction fluid, it continues to generate new bubbles as old bubbles burst during passage though the fiber. The energy of the bursting bubbles assists in extracting particles from the fiber filter into the reduced-volume sample. The majority of the bubbles in the extraction foam burst soon after release from the extraction cell, resulting in a much smaller volume sample, which is essentially liquid in nature.
- This application further incorporates by reference herein in their entirety all of the following applicant-owned applications, which disclose various techniques of foam elution, as discussed in the present disclosure Ser. No. 13/368,197; 12/814,993; 12/882,188; 12/883,137; 13/028,897. Such techniques are incorporated by reference in this application.
- The foregoing disclosure of the exemplary embodiments of the present subject disclosure has been presented for purposes of illustration and description. It is not intended to be exhaustive or to limit the subject disclosure to the precise forms disclosed. Many variations and modifications of the embodiments described herein will be apparent to one of ordinary skill in the art in light of the above disclosure. The scope of the subject disclosure is to be defined only by the claims appended hereto, and by their equivalents.
- Further, in describing representative embodiments of the present subject disclosure, the specification may have presented the method and/or process of the present subject disclosure as a particular sequence of steps. However, to the extent that the method or process does not rely on the particular order of steps set forth herein, the method or process should not be limited to the particular sequence of steps described. As one of ordinary skill in the art would appreciate, other sequences of steps may be possible. Therefore, the particular order of the steps set forth in the specification should not be construed as limitations on the claims. In addition, the claims directed to the method and/or process of the present subject disclosure should not be limited to the performance of their steps in the order written, and one skilled in the art can readily appreciate that the sequences may be varied and still remain within the spirit and scope of the present subject disclosure.
Claims (17)
1. A device for fractionation and concentration of particles from a fluid sample, the device comprising:
a cartridge containing staged filters having porous surface in series of decreasing pore size for capture of particles from a fluid sample; and
a permeate pressure source in fluid communication with the cartridge;
wherein the particles are eluted from the porous surfaces and dispensed in a reduced fluid volume.
2. The device in claim 1 , further comprising a connecting portion for connection to a concentrating unit.
3. The device in claim 1 , wherein the filters are separated by a small interstitial space.
4. The device in claim 1 , wherein the membrane filters are separated by a filter support with flow channel connecting the permeate of one filter with the retentate of an adjacent smaller pore filter.
5. The device in claim 1 , wherein a sample is introduced into the device perpendicular to a surface of each filter.
6. The device in claim 1 , wherein valved fluidic connections connect the interstitial space or flow channels between filters.
7. The device in claim 1 , wherein pneumatic, hydraulic, or mechanical valves are integrated into the cartridge device.
8. The device in claim 1 , wherein the filters are one or more of a flat membrane filter, a flat ceramic filter, an affinity-based filter, a flat depth filter, an electrostatically charged filter, or a microsieve.
9. The device in claim 1 , further comprising an elution buffer distribution manifold including flow control orifice.
10. The device in claim 1 , wherein elution is performed tangential to a surface of each filter.
11. A system for fractionation and concentration of particles from a fluid sample, the system comprising:
a reservoir holding a fluid sample;
a fractionation and concentration cartridge including two or more staged filters;
a permeate pressure device in fluid communication with the cartridge;
a concentrating unit including an actuating integral valving to move sample through the cartridge; and
a fluid dispenser source for collecting concentrated samples from the cartridge staged filters;
wherein the fluid sample is moved through the concentrating unit, then the concentrated samples are eluted from the filters and dispensed.
12. The system in claim 11 , wherein a flow sensor is in fluid communication with the sample flow into the cartridge.
13. The system in claim 11 , wherein a flow sensor is in fluid communication with the permeate flow out of the cartridge.
14. A method for rapid fractionation and concentration of particles from a fluid sample, the method comprising:
introducing a sample into the sample reservoir;
initiating a fractionation and concentration cycle;
passing the fluid sample through a series of filters;
eluting a plurality of particles of decreasing particle size from each filter stage; and
extracting a concentrated sample from each filter stage.
15. The method in claim 14 , wherein the eluting further comprises tangential flushing of a porous surface within the cartridge with an elution fluid.
16. The method in claim 15 , wherein the elution fluid is one or more of a liquid elution fluid and a wet foam.
17. The method in claim 14 , wherein blinding of the filter is prevented using one or more of high-frequency backpulsing and oscillating tangential flow.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US17/103,900 US20210148797A1 (en) | 2012-10-18 | 2020-11-24 | Liquid to liquid biological particle fractionation and concentration |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261715451P | 2012-10-18 | 2012-10-18 | |
US14/058,193 US10845277B2 (en) | 2012-10-18 | 2013-10-18 | Liquid to liquid biological particle fractionation and concentration |
US17/103,900 US20210148797A1 (en) | 2012-10-18 | 2020-11-24 | Liquid to liquid biological particle fractionation and concentration |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/058,193 Continuation US10845277B2 (en) | 2012-10-18 | 2013-10-18 | Liquid to liquid biological particle fractionation and concentration |
Publications (1)
Publication Number | Publication Date |
---|---|
US20210148797A1 true US20210148797A1 (en) | 2021-05-20 |
Family
ID=50488810
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/058,193 Active US10845277B2 (en) | 2012-10-18 | 2013-10-18 | Liquid to liquid biological particle fractionation and concentration |
US17/103,900 Pending US20210148797A1 (en) | 2012-10-18 | 2020-11-24 | Liquid to liquid biological particle fractionation and concentration |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/058,193 Active US10845277B2 (en) | 2012-10-18 | 2013-10-18 | Liquid to liquid biological particle fractionation and concentration |
Country Status (6)
Country | Link |
---|---|
US (2) | US10845277B2 (en) |
EP (1) | EP2984467B1 (en) |
CN (1) | CN104884933B (en) |
CA (1) | CA2927117C (en) |
ES (1) | ES2842525T3 (en) |
WO (1) | WO2014063125A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024091633A1 (en) * | 2022-10-26 | 2024-05-02 | Innovaprep Llc | Devices and methods for manipulation and concentration of particles and large molecules in a disposable filter tip |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9574977B2 (en) * | 2013-02-26 | 2017-02-21 | Innova Prep | Liquid to liquid biological particle concentrator with disposable fluid path |
US10436680B2 (en) | 2013-10-15 | 2019-10-08 | Kianoosh Peyvan | Capture, disruption, and extraction apparatus and method |
EP3071965A1 (en) | 2013-11-21 | 2016-09-28 | Avails Medical, Inc. | Electrical biosensor for detecting a substance in a bodily fluid, and method and system for same |
US9963733B2 (en) * | 2014-06-05 | 2018-05-08 | Avails Medical, Inc. | Devices, systems and methods for detecting viable infectious agents in a fluid sample |
JP6978408B2 (en) * | 2015-08-25 | 2021-12-08 | アバイルズ メディカル,インコーポレイテッド | Devices, systems and methods for detecting live microorganisms in fluid samples |
EP3356511B1 (en) * | 2016-01-25 | 2022-04-27 | Avails Medical, Inc. | Methods for detecting viable infectious agents in a fluid sample using an electrolyte-insulator-semiconductor sensor |
WO2017209839A1 (en) | 2016-05-31 | 2017-12-07 | Avails Medical, Inc. | Detecting viable infectious agents in a fluid sample and susceptibility of infectious agents to anti-infectives |
US10967352B1 (en) * | 2017-04-07 | 2021-04-06 | Triad National Security, Llc | Microfluidic liquid-liquid contactor |
WO2019005296A1 (en) | 2017-06-27 | 2019-01-03 | Avails Medical, Inc. | Apparatus, systems, and methods for determining susceptibility of microorganisms to anti-infectives |
CN111182971B (en) | 2017-10-03 | 2022-08-30 | 阿威尔斯医疗公司 | Devices, systems, and methods for determining the concentration of microorganisms and the sensitivity of microorganisms to anti-infective agents based on redox reactions |
EP3981500B1 (en) * | 2020-10-09 | 2023-06-21 | 12M Invent GmbH | A gas seperation system and gas seperation method comprising a membrane system having a control valve |
CN114062575A (en) * | 2021-11-29 | 2022-02-18 | 杭州富集生物科技有限公司 | Enrichment equipment and multi-sample continuous automatic enrichment method |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544423B1 (en) * | 1996-11-06 | 2003-04-08 | Mat Absorption Technologies Gmbh & Co. Kg | Membrane module for substance-specific fluid treatment |
US20030185974A1 (en) * | 2002-03-29 | 2003-10-02 | Mark Serafin | Classification of coating particle size |
US20090101575A1 (en) * | 2007-05-30 | 2009-04-23 | Alburty David S | Liquid To Liquid Biological Particle Concentrator |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3316540C1 (en) * | 1983-05-06 | 1984-11-29 | Gimbel, Rolf Dieter, Dr., 7505 Ettlingen | Method and device for separating turbid substances from liquids |
US5256294A (en) * | 1990-09-17 | 1993-10-26 | Genentech, Inc. | Tangential flow filtration process and apparatus |
AU674692B2 (en) * | 1992-07-13 | 1997-01-09 | Haemonetics Puerto Rico, Llc | Automatic processing of biological fluids such as whole bloodpacked red cells, platelet concentrate & plasma |
ES2356811T3 (en) * | 2001-09-20 | 2011-04-13 | Millipore Corporation | ELEMENT OF FLUID TRAVEL CONTROL FOR A FLUID TREATMENT MODULE. |
ATE494362T1 (en) * | 2002-05-14 | 2011-01-15 | Merck Sharp & Dohme | METHOD FOR PURIFYING ADENOVIRUS |
US7279134B2 (en) * | 2002-09-17 | 2007-10-09 | Intel Corporation | Microfluidic devices with porous membranes for molecular sieving, metering, and separations |
WO2005097304A1 (en) * | 2004-04-08 | 2005-10-20 | Mcmaster University | Membrane stacks |
US7510654B2 (en) * | 2005-12-29 | 2009-03-31 | Spf Innovations, Llc | Method and apparatus for the filtration of biological samples |
FR2934049B1 (en) * | 2008-07-16 | 2010-10-15 | Millipore Corp | UNIT AND METHOD FOR PREPARING A SAMPLE FOR THE MICROBIOLOGICAL ANALYSIS OF A LIQUID |
CA2736814C (en) * | 2008-09-02 | 2017-02-28 | Natrix Separations Inc. | Chromatography membranes, devices containing them, and methods of use thereof |
US8584535B2 (en) * | 2009-09-17 | 2013-11-19 | Innova Prep LLC | Liquid to liquid biological particle concentrator with disposable fluid path |
US8726744B2 (en) * | 2010-02-16 | 2014-05-20 | Innovaprep Llc | Portable concentrator |
EP4124856A1 (en) * | 2010-03-09 | 2023-02-01 | ANDE Corporation | Biochip with valve |
CN201728068U (en) * | 2010-06-02 | 2011-02-02 | 浙江华强环境科技有限公司 | Multilayer ultrafilteration membrane with irregular inner holes |
JP2012239991A (en) * | 2011-05-20 | 2012-12-10 | Seiko Epson Corp | Device for classifying fine particle |
-
2013
- 2013-10-18 CA CA2927117A patent/CA2927117C/en active Active
- 2013-10-18 EP EP13846911.9A patent/EP2984467B1/en active Active
- 2013-10-18 WO PCT/US2013/065800 patent/WO2014063125A1/en active Application Filing
- 2013-10-18 ES ES13846911T patent/ES2842525T3/en active Active
- 2013-10-18 CN CN201380066574.2A patent/CN104884933B/en active Active
- 2013-10-18 US US14/058,193 patent/US10845277B2/en active Active
-
2020
- 2020-11-24 US US17/103,900 patent/US20210148797A1/en active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6544423B1 (en) * | 1996-11-06 | 2003-04-08 | Mat Absorption Technologies Gmbh & Co. Kg | Membrane module for substance-specific fluid treatment |
US20030185974A1 (en) * | 2002-03-29 | 2003-10-02 | Mark Serafin | Classification of coating particle size |
US20090101575A1 (en) * | 2007-05-30 | 2009-04-23 | Alburty David S | Liquid To Liquid Biological Particle Concentrator |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024091633A1 (en) * | 2022-10-26 | 2024-05-02 | Innovaprep Llc | Devices and methods for manipulation and concentration of particles and large molecules in a disposable filter tip |
Also Published As
Publication number | Publication date |
---|---|
CA2927117C (en) | 2021-05-11 |
WO2014063125A1 (en) | 2014-04-24 |
CN104884933A (en) | 2015-09-02 |
US20140231256A1 (en) | 2014-08-21 |
EP2984467B1 (en) | 2020-10-14 |
CA2927117A1 (en) | 2014-04-24 |
EP2984467A4 (en) | 2017-01-04 |
EP2984467A1 (en) | 2016-02-17 |
CN104884933B (en) | 2019-03-01 |
ES2842525T3 (en) | 2021-07-14 |
US10845277B2 (en) | 2020-11-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210148797A1 (en) | Liquid to liquid biological particle fractionation and concentration | |
US20210215583A1 (en) | Liquid to liquid biological particle concentrator with disposable fluid path | |
US11747238B2 (en) | Liquid to liquid biological particle concentrator with disposable fluid path | |
US20200224242A1 (en) | Liquid to Liquid Biological Particle Concentrator | |
CA2940870C (en) | Liquid to liquid biological particle concentrator with disposable fluid path | |
US20210308664A1 (en) | Liquid to liquid biological particle concentrator with disposable fluid path | |
US20230358643A1 (en) | Liquid to Liquid Biological Particle Concentrator with Disposable Fluid Path |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: INNOVAPREP LLC, MISSOURI Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PACKINGHAM, ZACHARY ALLEN;PAGE, ANDREW EDWARD;ALBURTY, DAVID SCOTT;AND OTHERS;REEL/FRAME:054464/0580 Effective date: 20131018 |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |